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ABSTRACT
EVALUATING THE EFFECTS OF AROCLOR 1260 IN NON-ALCOHOLIC
FATTY LIVER DISEASE: THE ROLE OF XENOBIOTIC RECEPTORS

Banrida Wahlang
November 17, 2014

Polychlorinated biphenyls (PCBs) are persistent environmental toxicants,
present in 100% of US adults and dose-dependently associated with nonalcoholic fatty liver disease (NAFLD) in epidemiologic studies. PCBs are
predicted to interact with receptors previously implicated in xenobiotic/energy
metabolism and NAFLD. These receptors include the aryl hydrocarbon receptor
(AhR), pregnane xenobiotic receptor (PXR), constitutive androstane receptor
(CAR), peroxisome proliferator-activated receptors (PPARs), liver-X-receptor and
farnesoid-X-receptor.
This study evaluated the hepatic effects of the PCB mixture, Aroclor 1260,
whose composition mimics human bioaccumulation patterns, in a mouse model
of diet-induced obesity. Male C57Bl/6J mice were fed a control or 42% high fat
diet (HFD) and exposed to Aroclor 1260 (20 or 200 mg/kg in corn oil) for 12
weeks. Aroclor 1260 exposure was associated with decreased body fat in HFD-
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fed mice. Aroclor 1260+HFD co-exposed mice demonstrated increased
inflammatory foci at both doses while serum cytokines and hepatic expression of
IL-6 and TNFα were increased only at 20 mg/kg. Aroclor 1260 induced hepatic
Cyp3a11 (PXR target) and Cyp2b10 (CAR target) expression but Cyp2b10
inducibility was diminished with HFD-feeding. Cyp1a2 (AhR target) was induced
only at 200 mg/kg.
In PXR-/- and CAR-/- mice, Aroclor 1260 exposure resulted in
steatohepatitis with increased basal hepatic TNFα and IL-6 expression. PXR-/mice had increased % body fat and liver to body weight ratio regardless of
exposure. HOMA-IR decreased in all groups following Aroclor 1260 exposure.
PXR-/- mice exposed to Aroclor 1260 showed impaired glucose uptake, increased
hepatic gluconeogenic and lipogenic gene expression. The knockout groups
demonstrated increased basal mTOR1 activity while Aroclor 1260 exposure
increased AMPKα activity. Thus, PXR and CAR participate in hepatic energy
metabolism and are protective in Aroclor 1260-induced liver injury.
The study further evaluated Aroclor 1260 and selected congeners as
potential ligands for human receptors utilizing HepG2 and COS-1 cell lines; and
primary human hepatocytes. The results suggested that Aroclor 1260 is a human
AhR, PXR and CAR3 agonist, a mixed agonist/antagonist for CAR2 and an
antagonist for human PPARα.
In summary, Aroclor 1260 worsened hepatic inflammation in diet-induced
obesity. HFD decreased the protective CAR/PXR activation illustrating the
importance of dietary co-exposures in PCB-mediated steatohepatitis.
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CHAPTER 1
INTRODUCTION
Polychlorinated biphenyls (PCBs)
Polychlorinated biphenyls (PCBs) are polyhalogenated aromatic
hydrocarbons consisting of up to 10 chlorine atoms attached to a biphenyl group.
Depending on the number of chlorine atom substituents, there are 209 individual
PCB congeners that are theoretically possible. PCBs were commercially
produced during the 1930s-1970s and were used as dielectric and heat transfer
fluids in electric transformers and capacitors, wax extenders, organic diluents,
plasticizers, adhesives, flame retardants and as a source of chlorine content (1,
2). At least 1.3 million tons of PCBs, comprising about 130 identified individual
congeners, were manufactured worldwide prior to their banning (3). PCB
production was prohibited by the United States Congress in 1979 under the Toxic
Substances Control Act and PCB production was banned internationally at the
Stockholm Convention on Persistent Organic Pollutants in 2001 (4).
Although PCB production has been banned for over 30 years, their high
thermodynamic stability make them resistant to chemical and enzymatic
degradation in the environment (5) and hence, PCBs, belong to the category of
“persistent organic pollutants” (POPs). Moreover, PCBs persist in our ecosystem
globally due to PCB seepage into the environment, accidental spills and improper
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disposal and are found in soil, atmospheric air, lakes, rivers, aquatic wildlife and
mammals (6-10). In humans, PCBs, primarily the highly chlorinated congeners
that are resistant to metabolism, bio-accumulate and are detected in the adipose
tissue, liver, serum and breast milk (11, 12).
Currently, PCB exposure in humans is thought to occur primarily through
ingestion of PCB-contaminated food (13, 14) and to a lesser extent, through
inhalation of PCB-contaminated air (15, 16). In fact, PCBs continue to be present
in the food supply and the intake in the American diet is estimated to be
approximately 30 ng/day based on a study from a Dallas supermarket (17).
Furthermore, PCBs are the 5th most hazardous substances on the Agency for
Toxic Substances and Disease Registry (ATSDR) 2013 substance priority list.
The National Health and Nutrition Examination Study (NHANES) indicated that
100% of adult NHANES participants had detectable circulating PCB levels and
PCB 153 (2,2',4,4',5,5'-hexachlorobiphenyl) had the highest median serum
concentration in humans amongst all PCB congeners (18). Therefore, although
PCB production has stopped, these compounds are ubiquitous in the
environment and their resistance to degradation increases the risk of exposure in
humans.
PCBs’structure-activity and toxicity relationship
The PCB’s structure more or less determines the compound’s activity and
toxicity. PCBs can be classified as either “planar” or “non-coplanar” depending on
the number and nature of the chlorine substituents in the two phenyl rings, (Fig.
1.1). Planar PCBs have chlorine substitutions in either the meta- or para-
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positions but zero or one substituent in the ortho- positions (19). Non-coplanar
PCBs have ortho- substituted chlorine atoms, apart from meta- and/or parasubstitutions (19).
From a mechanistic standpoint, a PCB’s structure determines its ability to
interact with various receptors (20). PCB studies have demonstrated that planar
PCBs such as PCB 77 and PCB 126 interact with the aryl hydrocarbon receptor
(AhR) similar to the classic AhR ligand, 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin
(TCDD) and hence are also known as “dioxin-like” PCBs (21, 22). On the other
hand, some non-coplanar PCBs such as PCB 153 and PCB 196 are referred to
as “phenobarbital-like” PCBs suggesting their activation of the constitutive
androstane receptor (CAR) (22-24). Moreover, a theoretical structure-activity
relationship study predicted that non-coplanar PCBs can interact with the
pregnane xenobiotic receptor (PXR), estrogen receptor, androgen receptor, and
thyroid receptor as well (25).
Historically, PCB studies have focused on hepatocarcinogenesis and
other cancer-related endpoints and attributed the mechanism of toxicity to AhR
activation (26, 27). However, by mass, dioxin-like PCBs are a relatively minor
component of the total PCB burden in human serum (18). Moreover, PCBs do
not appear to be as carcinogenic in man as they are in rodents (eg: PCB 126),
and this may be due to differences in the AhR structure and in the battery of
target genes between species (28). In contrast to PCB 126, PCB 153 is an orthosubstituted, non-coplanar PCB. PCB 153 has been studied extensively by the
National Toxicology Program (NTP) in female Harlan Sprague-Dawley (SD) rats,
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and the mode of action has been attributed to the compound’s interaction with
CAR (23). The studies also demonstrated PCB-induced hepatotoxicity.
Apart from the structure, a PCB congener’s molecular weight which
corresponds to the degree of chlorination also dictates the type of toxicity. PCB’s
metabolism is defined by the number of chlorine atoms present. Low molecular
weight PCBs (mono-, di-, tri- or tetra-chlorinated) are hydroxylated by
cytochrome P450 enzymes (29). The metabolized PCBs, also known as biotransformed congeners, can form DNA adducts or bind to proteins to exert their
toxic effects. High molecular weight PCBs, on the other hand, are resistant to
metabolism, hence they are known as persistent congeners. Some of these
PCBs’ half-life is >15 years (30). These lipid-soluble PCBs, including the pentachlorinated PCB 126 and hexa-chlorinated PCB 153, bio-accumulate primarily in
the adipose tissue and have the ability to interact with receptors (1).
Therefore, depending on the molecular weight of the congener and the
molecular structure, PCBs have a tendency to induce carcinogenesis by forming
adducts and through AhR activation. PCB exposure can also cause other
complications, such as endocrine disruption through other PCB-receptor
interactions. Additionally, apart from PCB-receptor interactions, nutrient-toxicant
interactions have also been reported to play a role in health disorders such as
diet-induced obesity/metabolic syndrome (31) and non-alcoholic fatty liver
disease (NAFLD) (32).
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Figure 1.1. Chemical structure of PCBs.
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The PCB mixture, Aroclor 1260
PCBs were commercially marketed and used as mixtures rather than
individual congeners. Monsanto, a well-known PCB manufacturer in North
America, produced PCB mixtures under the brand name “Aroclor” at its
manufacturing plant located in Anniston, Alabama. Incidences of high-level
environmental contamination during PCB production resulted in increased PCB
body burden in the Anniston residents (33, 34). PCB production was global with
PCB mixtures being manufactured worldwide under different brand names
including Clophens (Germany), Phenoclors and Pyralenes (France), Fenclors
(Italy), Fenochlors (Spain), Kanechlors (Japan) and Sovol (former USSR) (2).
Aroclor 1260, a commercial PCB mixture, contained 60% chlorine by
weight. It was one of the first generation PCB mixtures produced by Monsanto
during the early stages of PCB production. Aroclor 1260 was later replaced by
other Aroclors such as Aroclor 1254, Aroclor 1248 and Aroclor 1242 that had
lower chlorine content by weight (2). Aroclor 1260 is heavily chlorinated and
contains a limited amount of coplanar congeners (∼1%) (19). It has
predominantly non-coplanar and di-ortho substituted PCBs that have either 5, 6,
7, or 8 chlorines (Table 1). As PCBs with low molecular weight are often
metabolized and eliminated, PCBs that bio-accumulate in humans are typically
the highly chlorinated congeners with penta-, hexa-, hepta-, and octa
substituents (35, 36). Thus, for our PCB studies, we selected the PCB mixture
Aroclor 1260 because its composition best mimics the PCB bioaccumulation
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profile found in human adipose tissue, rather than reflecting the actual production
volume of PCBs (Fig. 1.2).
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PCB

No. of chlorine

Ortho substitution

%

180

7

(Non-coplanar, di-ortho)

11.38

153

6

(Non-coplanar, di-ortho)

9.39

149

6

(Non-coplanar, tri-ortho)

8.75

138

6

(Non-coplanar, di-ortho)

6.54

187

7

(Non-coplanar, tri-ortho)

5.40

174

7

(Non-coplanar, tri-ortho)

4.96

170

7

(Non-coplanar, di-ortho)

4.11

101

5

(Non-coplanar, di-ortho)

3.13

151

6

(Non-coplanar, tri-ortho)

3.04

132

6

(Non-coplanar, tri-ortho)

2.90

141

6

(Non-coplanar, di-ortho)

2.62

177

7

(Non-coplanar, tri-ortho)

2.57

95

5

(Non-coplanar, tri-ortho)

2.45

163

6

(Non-coplanar, di-ortho)

2.42

183

7

(Non-coplanar, tri-ortho)

2.41

194

8

(Non-coplanar, di-ortho)

2.07

179

7

(Non-coplanar, tetra-ortho)

2.03

136

6

(Non-coplanar, tetra-ortho)

1.46

203

8

(Non-coplanar, tri-ortho)

1.40

110

5

(Non-coplanar, di-ortho)

1.33

146

6

(Non-coplanar, di-ortho)

1.15

171

7

(Non-coplanar, tri-ortho)

1.11

196

8

(Non-coplanar, tri-ortho)

1.09

135

6

(Non-coplanar, tri-ortho)

1.08

congener

Table 1. PCB congener composition in Aroclor 1260.
Selected PCB congeners present in Aroclor 1260 (≥1% of total composition).
Table adapted from www.atsdr.cdc.gov/toxprofiles/tp17-c4.pdf.
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Figure 1.2. Congener composition in human fat, Aroclor 1260 and
manufactured PCBs.
Pie charts depicting the relative abundance of PCB congeners in human
adipose tissue, Aroclor 1260 and manufactured PCBs.
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Effects of PCB exposure in humans
Historically, PCB toxicity has been linked to cancer, endocrine disruption
and impaired cognitive development (37-40), but recent epidemiologic studies
have shown that chronic exposure to these environmental pollutants can result in
metabolic disorders associated with fatty liver disease, including obesity, insulin
resistance/diabetes and the metabolic syndrome (18, 34, 41-44). Moreover, other
complications associated with metabolic disorders such as hypertension and
cardiovascular disorders have also been associated with PCB exposure (45, 46).
Furthermore, a follow-up of subjects in the “Yu-cheng” incident in Taiwan
demonstrated that the mortality rate due to cirrhosis was 2.7-fold higher than
expected, although pathologic confirmation was not provided (47). The “Yucheng” incident was one of the two known major human PCB intoxication
episodes, where the victims ingested cooking oil that was highly contaminated
with PCBs. Additionally; rodent studies have correlated PCB exposures with
NAFLD, obesity and the metabolic syndrome (48, 49).
Our laboratory group recently identified advanced steatohepatitis
associated with insulin resistance and increased pro-inflammatory cytokines in
non-obese chemical workers who were subjected to high-level industrial
chemical exposures (50). The term “toxicant-associated steatohepatitis” (TASH)
was then coined to describe this condition (51). Our initial work focused on TASH
in non-obese vinyl chloride workers; in our recent work however, our laboratory
group identified suspected NAFLD and TASH in the NHANES participants with
low-level environmental exposures to POPs, including 20 PCBs (18).
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Epidemiologic studies have reported a positive association between adipose
tissue concentrations of PCBs and type 2 diabetes (52). High serum PCB levels
were also associated with elevated serum triglycerides and cholesterol which are
major risk factors for cardiovascular diseases. Exposure to PCB mixtures has
also been associated with elevated liver enzymes in plasma and hepatomegaly
(18, 53). Clearly, environmental exposure to POPs such as PCBs is a major
health concern, with emerging studies reporting positive associations between
PCB body burden and suspected liver disease. However, studies involving the
non-carcinogenic effects of PCB exposure on the liver are scarce and therefore,
more research is required to evaluate the role of PCB exposure in liver disease,
particularly NAFLD.
Non-alcoholic fatty liver disease and xenobiotic receptors
NAFLD represents a pathological spectrum of diseases ranging from lipid
accumulation in the hepatocytes (steatosis) to the development of superimposed
inflammation, leading to non-alcoholic steatohepatitis (NASH) and ultimately
fibrosis and cirrhosis. NAFLD resembles alcoholic fatty liver disease, although it
occurs in subjects who do not consume excessive amounts of alcohol. The
pathogenesis of NAFLD has been reviewed, and key mechanisms included
altered adipo-cytokines with low adiponectin and high leptin levels (32, 54) and
elevation of pro-inflammatory cytokines such as TNFα and IL-6 (55). NAFLD
gives rise to hepatic insulin resistance and systemic inflammation, which in turn,
exacerbates obesity, diabetes and the metabolic syndrome (56). Because it is
often seen with insulin resistance and dyslipidemia, NAFLD is generally regarded
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to be the hepatic manifestation of obesity and the metabolic syndrome. However,
NAFLD is also exacerbated by diabetes and is associated with obesity (57),
indicating a vicious cycle between NAFLD, diabetes/insulin resistance and
obesity.
NAFLD and NASH were traditionally associated with the inappropriate
over- or under-activation of nuclear receptors involved in endobiotic metabolism.
These receptors include the liver-X-receptor (LXR), farnesoid-X-receptor (FXR)
and peroxisome proliferator-activated receptors (PPARs) which regulate
cholesterol, bile acid and lipid metabolism respectively (58, 59). Recent studies
have implicated the role of hepatic receptors involved in xenobiotic detoxification,
including PXR, CAR and AhR in NAFLD/NASH. Although these receptors were
initially thought to be involved only with detoxification and xenobiotic metabolism,
over-activation or antagonism of these receptors may lead to metabolic diseased
states such as steatosis and obesity (60-62). Notably, PCBs have been
demonstrated to interact with AhR, CAR and PXR (22-24, 26, 27). Therefore, it is
pertinent to study the activation of these xenobiotic receptors by PCBs and their
contribution to NAFLD with PCB exposure.
The AhR is a member of the Per Arnt Sim (PAS) domain protein family of
transcription factors and regulates a battery of genes involved in xenobiotic
detoxification including CYP1A and CYP1B which can, in turn, bio-transform or
activate pro-carcinogens to their carcinogenic forms (63, 64). Apart from
xenobiotic detoxification, the AhR also plays a role in the differentiation of
developmental pathways such as hematopoiesis (65) and in regulating
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immunological responses (66). Furthermore, previous work also implicated
dioxins and dioxin-like PCBs in animal models of steatohepatitis (67, 68).
On the other hand, PXR, also known as the steroid and xenobiotic sensing
nuclear receptor (nuclear receptor subfamily 1, group I, member 2, NR1I2) and
CAR (nuclear receptor subfamily 1, group I, member 3, NR1I2NR1I3) belong to
the class of nuclear receptors; upon activation by ligands, PXR and CAR
transcriptionally activate numerous target genes that encode enzymes and
transporters involved in drug and xenobiotic metabolism (69). However, recent
studies have demonstrated these receptors’ role in energy homeostasis and
these include regulation of lipid and carbohydrate metabolism (60, 70). CAR was
recently named as an anti-obesity nuclear receptor, since its activation improves
insulin sensitivity in a diet-induced obesity mouse model and ameliorates
diabetes and fatty liver disease in leptin-deficient mice (71, 72). Activating CAR
and PXR also induced the anti-lipogenic protein, Insig (73). Furthermore, PXR
and CAR activation also suppressed gluconeogenesis by decreasing
gluconeogenic gene expression including phosphoenol-pyruvate carboxykinase
and glucose-6-phosphatase (74). The reported role of PXR in obesity is
controversial with some studies demonstrating obesity-protecting effects of PXR
activation (75) and others illustrating that ablating PXR alleviated diet-induced
obesity (76, 77). CAR and PXR exert these effects through interactions with other
transcription factors and receptors including direct protein sequestration.
Activated nuclear receptors bind to the respective DNA-response elements in the
promoter regions of the target genes using their conserved DNA-binding domains
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and promote gene expression (78). These response elements are made up of
hexameric sequences that can be arranged in different configurations to give
direct repeats (DR) or inverted repeats. CAR and PXR can bind to similar DNAresponse elements in the promoter region, increasing the probability of crosstalk.
Therefore, CAR and PXR activation can result in crosstalk with other receptors
and possibly activation of genes that are not necessarily CAR or PXR targets.
Significance of studying liver disease
NAFLD affects up to 46% of the US population and approximately 20% of
the population worldwide and it is the most prevalent liver disease in North
America (79-81). It is more common in men than women until the age of 60 when
the prevalence matches and the lower rate of NAFLD in women is attributed to
the protective nature of estrogen in fatty liver disease. The prevalence of NAFLD
is still growing and it is higher in the Hispanic population, which can be attributed
to high rates of obesity and type 2 diabetes in this population (82). NAFLD is not
an independent entity by itself but it is closely related to obesity, insulin
resistance and the metabolic syndrome. The association between NAFLD and
obesity poses a great concern to human health because obesity has been
identified as a leading “preventable cause of death” by the World Health
Organization (WHO), and many health authorities view it as one of the most
serious health problems of the 21st century. The annual cost of obesity treatment
in the US alone was recently estimated at $147 billion (83) . According to the
data from NHANES 2007-2008, 33.8% of US adults are obese (defined by body
mass index, BMI ≥ 30) with another 34.2% being overweight (defined by BMI ≥
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25). Alarmingly, obesity is not restricted to the adult population; 15% of children
and adolescents in the US are obese (84). Overweight/obesity is one of the
defining features of the metabolic syndrome, a metabolic disorder which is also
characterized by insulin resistance, hypertension, and dyslipidemia. The
prevalence of metabolic syndrome in US adults was recently estimated at 34.3%.
The obesity epidemic is strongly associated with increased type 2 diabetes which
is the late stage of insulin resistance. The National Diabetes Fact Sheet obtained
from the Center for Disease Control and Prevention (CDC, 2011) reports that
25.8 million Americans have diabetes with another 79 million being insulin
resistant. Obesity, insulin resistance, and metabolic syndrome can eventually
lead to target organ damage contributing to cardiovascular disease, chronic
kidney disease, and cancer (85-87). Therefore, taking the above mentioned
statistics into consideration, studying the causal factors of NAFLD is relevant to
public health.
Overall goal and specific aims
The pathogenesis of NAFLD, obesity, insulin resistance, and the
metabolic syndrome is complex. NAFLD and obesity were linked to high caloric
intake and over-nutrition, physical inactivity, genetic background, and certain
medications’ side effects. Interestingly, inflamed and fatty liver conditions are not
confined to obese individuals only, but other factors can predispose a person to
steatohepatitis. It is possible that primary factors such as consumption of hypercaloric foods can lead to steatosis in normal individuals, thus acting as a ‘first hit’.
Emerging studies have demonstrated that other factors may play a role in the
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genesis and development of NAFLD or may act as a ‘second hit’ in the
progression of hepatic steatosis to steatohepatitis (88). These factors may
include exposure to environmental contaminants including PCBs,
bromodichloromethane (BDCM) and organochlorine pesticides, such as, dieldrin
and dichlorodiphenyltrichloroethane (DDT) (41, 89). Our laboratory group
recently identified industrial chemicals and environmental pollutants that are
associated with toxicant-associated fatty liver disease and toxicant-associated
steatohepatitis (TASH) using two federal databases (90). Such compounds have
the capacity to act as key players in the development of NASH, obesity and the
metabolic syndrome but the number of studies on the effects of environmental
pollutants in liver disease is still modest and needs to be investigated.
The overall goal of this dissertation is to evaluate the role of PCB
exposure in fatty liver disease and elucidate the potential PCB-receptor
interactions that mediate fatty liver disease. The outcomes from this study would
benefit our understanding of TASH and the underlying mechanisms caused by
toxicant exposure in TASH. The specific aims of the project are as follows:
1A. Develop a mouse model for PCB exposure that simulates human
exposure paradigms.
1B. Evaluate the effects of the commercialized PCB mixture, Aroclor
1260, in obesity and NAFLD.
The congener composition in the PCB mixture, Aroclor 1260, resembles
bio-accumulated PCBs present in human adipose tissue (Fig. 1.2) and it was
therefore chosen for this study. Prior to initiating the animal experiments
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described in this dissertation, there were no documented studies on animal
models using PCB mixtures that simulate bio-accumulated PCBs and at doses
relevant to human exposure. Additionally, the effects of Aroclor 1260 in dietinduced steatosis and obesity have never been assessed. The purpose of the
studies in Chapter 2 was to develop a mouse model to study the effects of PCB
exposure at doses relevant to human exposure. Additionally, the experiments in
Chapter 2 were designed to determine if Aroclor 1260 exposure by itself could
induce NAFLD or if it worsens NAFLD and obesity caused by high fat diet
feeding.
2. Determine the role of the nuclear receptors, CAR and PXR, in liver
injury caused by Aroclor 1260 and high fat diet co-exposure.
CAR and PXR are involved in drug metabolism but recent studies have
demonstrated in the role of these receptors in maintaining energy homeostasis in
the body (60-62). Moreover, theoretical structure activity relationship studies
predicted that non-coplanar PCBs can interact with CAR and PXR (25).
However activation of CAR and PXR by a PCB mixture and the subsequent
contribution of these activated receptors to PCB effects and toxicity have not
been thoroughly evaluated, especially in terms of obesity and NAFLD/NASH. The
experiments described in Chapter 3 examined the role of CAR and PXR in the
context of liver injury caused by Aroclor 1260 exposure and high fat diet feeding.
3. Examine the interactions between Aroclor 1260/selected PCB
congeners and human receptors in the liver
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We hypothesized that PCBs may exert some of their toxic effects, such as
NAFLD, by interacting directly with the endobiotic nuclear receptors (LXR, FXR,
PPARs) or with xenobiotic receptors (AhR, CAR and PXR). Moreover, the
interaction between Aroclor 1260 and these receptors that are implicated in
NAFLD have never been tested. The purpose of the studies in Chapter 4 is to
evaluate human receptor agonism/antagonism by the PCB mixture, Aroclor 1260,
and selected PCB congeners that are highly represented in this mixture. We
determined human receptor activation by utilizing transient transfection assays in
human hepatoma-derived (HepG2) and primate-derived (COS-1) cell lines.
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CHAPTER 2
EVALUATING THE EFFECTS OF AROCLOR 1260 IN A DIET-INDUCED
OBESITY MOUSE MODEL
INTRODUCTION
As aforementioned, previous studies on PCBs were focused on
carcinogenicity and acute toxicity; however, the effects of chronic low-level
exposures to PCBs on other pathologies such as NAFLD, diabetes and obesity
are understudied, especially for PCB mixtures. Epidemiological studies have
found associations between PCB exposures and metabolic disorders related to
NAFLD, including obesity, diabetes/insulin resistance and the metabolic
syndrome. In our recent work, we demonstrated that PCB 153 administration was
a relevant ‘second hit’ mechanism that worsened NAFLD/obesity occurring in the
context of a high fat diet (HFD) in male C57Bl/6 mice (48). However, no
individual is exposed to a single PCB congener alone and therefore studying a
PCB mixture may better simulate human PCB exposure patterns. Moreover, the
composition of PCB congeners in Aroclor 1260 mimics human bioaccumulation
patterns (36).
The primary toxicity endpoint of PCB exposure has been an increase in
cancer and is thought to be mediated through PCB interaction with transcription
factors namely the AhR. Genotoxic carcinogenic mechanisms are activated via
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induction of the AhR and the carcinogenicity of a PCB mixture is often defined as
its ability to induce the AhR-dependent gene transcription relative to the potent
rodent carcinogen and prototypical AhR ligand, TCDD. In addition, “non
genotoxic” carcinogenic mechanisms may also be induced including
hepatomegaly by the nuclear receptors, CAR and PXR. Although these receptors
are primarily involved in xenobiotic detoxification, recent studies have implicated
their role in metabolic diseased states such as steatosis, obesity and insulin
resistance (60-62). The role of hepatic receptor-PCB interactions in NASH and
the metabolic syndrome is understudied and requires further investigation.
It is therefore pertinent to evaluate the effects of a commercially produced
PCB mixture whose composition is relevant to human PCB body burden, in a
normal and hyper- caloric state, and investigate nutrient-toxicant interactions that
can contribute to liver disease and obesity. We hypothesize that the commercial
PCB mixture, Aroclor 1260, like PCB 153, can act as an obesogen and
promote/worsen steatosis and diet-induced obesity. In this study, we utilized a
mouse model to determine if i) Aroclor 1260 exposures alone are sufficient to
cause NAFLD and obesity; ii) Aroclor 1260 worsens diet-induced obesity and
NAFLD by exacerbating insulin resistance, adipocytokine dysregulation,
alterations in hepatic gene expression, AhR, PXR and CAR activation and other
implicated mechanisms; and iii) effects observed with Aroclor 1260
administration are dependent on PCB dose.
The results of the current study established Aroclor 1260 as a “second hit”
driving steatosis to steatohepatitis in HFD-fed mice. The results also
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demonstrated that selective hepatic receptor activation by this PCB mixture was
dependent on exposure dose and diet, in part, clarifying the mechanism of action
of PCBs in fatty liver disease.
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MATERIALS AND METHODS
Animals and diets
The animal protocol was approved by the University of Louisville
Institutional Animal Care and Use Committee. Male C57Bl/6J mice (8 weeks old;
The Jackson Laboratory, Bar Harbor, ME, USA) were divided into 6 study groups
(n=10) based on diet and Aroclor 1260 exposure in this 12 week study utilizing a
2x3 design. Mice were fed either a control diet (CD, 10.2% kCal from fat;
TD.06416 Harlan Teklad) or a HFD (42% kCal from fat; TD.88137 Harlan
Teklad). Diet components are described in Table 2. Aroclor 1260 (AccuStandard,
CT, USA) was administered in corn oil by oral gavage (vs. corn oil alone) at two
doses; a low dose of 20 mg/kg which was designed to mimic the maximum
human PCB exposures seen in the Anniston cohort and a high dose of 200
mg/kg which was similar to that used in rodent carcinogenesis studies (18, 22).
The 20 mg/kg dose was administered on Week 1 whereas the 200 mg/kg dose
was administered as four individual doses of 50 mg/kg each on Weeks 1, 3, 5,
and 7 to ensure that acute toxicity was minimized (Fig. 2.1). Mice were housed in
a temperature- and light controlled-room (12 hour light; 12 hour dark) with food
and water ad libitum. A glucose tolerance test was performed at Week 11, and
the animals were euthanized (ketamine/ xylazine, 100/20 mg/kg body weight,
i.p.) at the end of Week 12. Prior to euthanasia, the animals were analyzed for
body fat composition by dual energy X-ray absorptiometry (DEXA) scanning
(Lunar PIXImus densitometer, WI, USA). Thus six different treatment groups
were evaluated in this fashion: CD+vehicle, CD+Aroclor 1260 (20 mg/kg),
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CD+Aroclor 1260 (200 mg/kg), HFD+vehicle, HFD+Aroclor 1260 (20 mg/kg),
HFD+Aroclor 1260 (200 mg/kg).
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Control Diet

High Fat Diet

%kCal

Source

%kCal

Source

Protein

20.1

Casein

15.2

Casein

Carbohydrate

69.8

Fat

10.2

kCal/g

3.7

Sucrose/Corn
starch
Lard

42.7

42
4.5

Table 2. Diet composition.
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Sucrose/Corn
starch
Anhydrous
Milkfat

Figure 2.1. Experimental design and timeline
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Glucose tolerance test
On the day of the test, mice were fasted for 6 h (7a.m.-1 p.m.), and fasting
blood glucose levels were measured with a hand-held glucometer (ACCUCHECK Aviva, Roche, Basel, Switzerland) using 1-2 µL blood via tail snip.
Glucose was then administered (1 mg glucose/g body weight, sterile saline, i.p.),
and blood glucose was measured at 5, 15, 30, 60, 90 and 120 min post injection.
Insulin resistance was calculated by homeostasis model assessment using the
formula: homeostasis model assessment of insulin resistance (HOMAIR)=Fasting glucose (mg/dL) x Fasting insulin (µU/mL)/405.
Histological studies
Liver and adipose sections were fixed in 10% neutral buffered formalin
and embedded in paraffin for routine histological examination. Tissue sections
were stained with hematoxylin-eosin (H&E) or for chloroacetate esterase activity
[CAE, Naphthol AS-D Chloroacetate (Specific Esterase) Kit, Sigma Aldrich, St.
Louis, MO, USA] and examined by light microscopy. Photomicrographic images
were captured using a high-resolution digital scanner at 10x and 40x
magnification. After H&E staining, adipocyte size was measured using Image J
software version 1.47 (NIH, Bethesda, MD, USA).
Cytokine and adipokine measurement
Plasma cytokine and adipokine levels were measured using the Milliplex
Serum Cytokine and Adipokine Kits (Millipore Corp, Billerica, MA, USA) on the
Luminex IS 100 system (Luminex Corp, Austin, TX, USA), as per the
manufacturer’s instructions. Plasma aspartate transaminase (AST) activity,
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alanine transaminase (ALT) activity, low density lipoprotein (LDL), high density
lipoprotein (HDL), triglycerides and cholesterol levels were measured with the
Piccolo Xpress Chemistry Analyzer using Lipid Panel Plus reagent discs (Abaxis,
Union City, CA, USA).
Measurement of hepatic triglyceride and cholesterol content
Mouse livers were washed in neutral 1X phosphate buffered saline and
pulverized. Hepatic lipids were extracted by an aqueous solution of chloroform
and methanol, according to the Bligh and Dyer method (91), dried using nitrogen,
and resuspended in 5% lipid-free bovine serum albumin. Triglycerides and
cholesterol were quantified using the Cobas Mira Plus automated chemical
analyzer. The reagents employed for the assay were L-Type Triglyceride M
(Wako Diagnostics, Richmond, VA, USA) and Infinity Cholesterol Liquid Stable
Reagent (Fisher Diagnostics, Middletown, VA, USA) for triglycerides and
cholesterol respectively.
Real-time PCR
Animal liver and adipose tissue samples were homogenized and total
RNA was extracted using the RNA-STAT 60 protocol (Tel-Test, Austin, TX,
USA). RNA purity and quantity were assessed with the Nanodrop (ND-1000,
Thermo Scientific, Wilmington, DE, USA) using the ND-1000 V3.8.1 software.
cDNA was synthesized from total RNA using the QuantiTect Reverse
Transcription Kit (Qiagen, Valencia, CA, USA). Polymerase Chain Reaction
(PCR) was performed on the Applied Biosystems StepOnePlus Real-Time PCR
Systems using the Taqman Universal PCR Master Mix (Life Technologies,
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Carlsbad, CA, USA). Primer sequences for Taqman Gene Expression Assays
(Applied Biosystems, Foster City, CA) were as follows: tumor necrosis factor
alpha (TNFα); (Mm00443258-m1), fatty acid synthase (FAS); (Mm00662319m1), peroxisome proliferator-activated receptor alpha (PPARα); (Mm00440939m1), carnitine palmitoyl transferase 1A (CPT1A); (Mm01231183-m1), sterol
regulatory element binding protein (SREBP-1c); (Mm00550338-m1), cytochrome
P450s [Cyp4a10 (Mm02601690-gH), Cyp2b10 (Mm01972453-s1), Cyp3a11
(Mm007731567-m1), Cyp1a2 (Mm00487224-m1)], CD36 (Mm01135198-m1),
phosphoenolpyruvate carboxy kinase (PEPCK-1); (Mm01247058-m1), stearoyl
coenzyme A desaturase1 (SCD1); (Mm00772290-m1), interleukin 6 (IL-6);
(Mm00446190-m1), monocyte inducible protein 1 (MIP1); (Mm00441258-m1),
monocyte chemo attractant protein 2 (MCP2); (Mm01297183-m1), transforming
growth factor-beta (TGFβ); (Mm01178820_m1), collagen 1α1
(Mm00801666_g1), tissue inhibitor of metalloproteinases-1 (TIMP-1);
(Mm00441818_m1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH);
(4352932E). The levels of mRNA were normalized relative to the amount of
GAPDH mRNA, and expression levels in mice fed control diet and administered
vehicle were set at 1. Gene expression levels were calculated according to the
2−∆∆Ct method (92).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism version 5.01
for Windows (GraphPad Software Inc., La Jolla, CA, USA). Data are expressed
as mean ± SEM. Multiple group data were compared using One Way ANOVA

28

followed by Bonferroni's post-hoc test (for parametric data) or Kruskal-Wallis test
followed by Dunn’s Multiple Comparison Test (for nonparametric data). P <0.05
was considered statistically significant.

29

RESULTS
Aroclor 1260 decreased body weight and visceral adiposity in mice fed
high fat diet, but had no effect in mice fed control diet
During the 12-week study, body weight gain was measured and percent
(%) increase in bodyweight was calculated (Fig. 2.2 A&B). All the HFD groups
experienced weight gain vs. CD groups. Aroclor 1260 administration did not
further increase the body weight of mice consuming HFD. Rather, Aroclor 1260
at 200 mg/kg decreased the body weight gain in HFD-fed mice vs. HFD+vehicle
group (171.7±8.9% vs. 156.9±11.3%, p <0.05). Aroclor 1260 at 20 mg/kg had no
effect on body weight in HFD or CD groups. The % body fat composition was
evaluated by DEXA scanning prior to harvesting the animals (Fig. 2.2 C). HFD
consumption increased total body fat. Aroclor 1260 at both doses diminished the
increase in % body fat composition in HFD-fed mice (p <0.05) but not in CD-fed
mice. In fact, mice co-exposed to HFD and Aroclor 1260 (20 mg/kg) appeared to
have an increase in lean body mass as compared to HFD-fed mice only (Fig. 2.2
D). There were no differences in % fat composition in CD-fed mice exposed to
Aroclor 1260 vs. CD+vehicle group. The pattern of epididymal fat to body weight
ratio among the six groups was similar to the pattern of body fat composition
obtained by DEXA scanning, further supporting the observation that Aroclor 1260
exposure attenuated the increase in % body fat caused by HFD feeding (Fig. 2.2
E).
Mean epididymal adipocyte area (µm2) was larger in HFD+vehicle vs.
CD+vehicle (p <0.05). However, Aroclor 1260 had no effect at any of the doses
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administered, either in mice fed CD or HFD (Fig. 2.2 F&G). Food consumption
per mouse per day (g) was calculated over the 12-week period of study. Although
all the HFD groups of animals consumed more food (approximately 1.7-fold more
calories) as compared to CD groups, Aroclor 1260 did not alter the food
consumption rate (Fig. 2.2 H). Thus, Aroclor 1260 exposure at both doses did not
increase diet-induced adiposity or adipocyte size.
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Figure 2.2. Effects of Aroclor 1260 exposure on body weight and visceral
adiposity.
(A) Increase in body weight with time for C57BL/6 mice (n=10) fed with a
42% milk fat diet (vs. CD). Body weight measurements were taken from Week 1
to Week 12 (12 weeks). (B) The % increase in body weight gain with time was
calculated and the body weight at Week 1 was taken as 100%. (C) The % fat
composition was measured using the Lunar PIXImus densitometer (DEXA
scanner). Aroclor 1260 (20 and 200 mg/kg) exposure lowered % fat composition
in HFD-fed mice vs. HFD+vehicle group. (D) The lean tissue mass (g) was also
measured using the DEXA scanner. (E) Epididymal weight (EW) to body weight
(BW) ratio was calculated for all groups of mice. (F & G) Epididymal adipose
tissue was stained with H&E. and the adipocyte size (µm2) was measured. The
average cell size of >100 cells for each group was calculated. (H) Food
consumption throughout the 12-week study was measured. Values are mean ±
SEM, p <0.05, a- ∆ due to HFD. CD-control diet, HFD-high fat diet, Ar-Aroclor
1260. Figure adapted from Wahlang et al., Toxicol Appl Pharmacol, 279 (3),
2014.
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Aroclor 1260 exposure caused increased liver injury in HFD-fed mice
CD-fed mice with or without Aroclor 1260 exposure did not develop
steatosis or steatohepatitis as seen with H&E staining of the liver sections (Fig.
2.3 A). Mice fed with HFD developed steatosis in both the unexposed and
Aroclor 1260-exposed groups. The most striking difference between the HFD and
HFD+Aroclor 1260 groups was transformation from steatosis to steatohepatitis.
HFD+Aroclor 1260 co-exposures resulted in scattered foci of mononuclear cells
and neutrophils (confirmed with CAE stained slides) and hepatocyte necrosis
which appeared greater in the high dose group (Fig. 2.3 A&B). Aroclor 1260
exposure was associated with centrilobular enlargement of hepatocytes and
karyomegaly irrespective of diet type, possibly reflecting hepatic enzyme
induction in these mice. Liver to body weight ratio was calculated and there were
no differences among the groups (Fig. 2.3 C). No inflammation was observed in
Aroclor 1260-exposed mice fed CD.
Liver injury, as determined by elevated serum ALT levels, was most
noticeable in the HFD+Aroclor 1260 (20 mg/kg) group (p <0.05) while serum AST
was unaffected (Fig. 2.3 D&E). Although the higher exposure group (200 mg/kg)
fed HFD tended to have more inflammatory foci based on histological
assessment, serum ALT levels were not significantly elevated in this group. In
the CD-fed mice, Aroclor 1260 exposure did not alter the serum ALT and AST
levels at either dose. Hepatic expression of fibrotic markers including
transforming growth factor-beta (TGFβ), collagen 1α1 and tissue inhibitor of
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metalloproteinases-1 (TIMP-1) were measured (Fig. 2.3 F,G&H) and there was
no increase in mRNA levels among the HFD groups.
The HFD+vehicle group showed a significant increase in hepatic levels of
cholesterol and triglycerides vs. any of the CD groups (Fig. 2.4 A&B). However,
hepatic cholesterol and triglycerides levels were not significantly increased in the
HFD+Aroclor 1260 at 20 or 200 mg/kg vs. any of the CD groups. Likewise,
hepatic cholesterol and triglycerides levels were not significantly increased in the
HFD+Aroclor 1260 at 20 or 200 mg/kg vs. the HFD group alone. Rather, there
was a trend towards decreased hepatic cholesterol and triglycerides with Aroclor
1260 exposure in HFD-fed mice but this was not significant. Taken together,
these results suggest that Aroclor 1260 exposure did not worsen steatosis
caused by HFD but augmented inflammation and induced steatohepatitis
instead.
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Figure 2.3. Aroclor 1260 exposure caused steatohepatitis in HFD-fed mice
but had no effect on fibrotic markers.
(A) H&E staining of hepatic sections established the occurrence of
centrilobular hepatocellular hypertrophy, karyomegaly, and multinucleate (arrow
head) hepatocytes in the CD+Aroclor 1260 (200mg/kg) group [A]. HFD
consumption resulted in variable, centrilobular, microvesicular lipidosis [B-D],
while centrilobular hepatocellular hypertrophy was observed in HFD+Aroclor
1260 (20mg/kg) mice [C]. HFD-fed mice exposed to Aroclor 1260 (200mg/kg)
exhibited occasional, small areas of necrosis and inflammation (steatohepatitis)
[D], characterized by neutrophils (arrow head) and pyknotic debris (arrow). (B)
CAE staining demonstrated neutrophil infiltration in the HFD+Aroclor 1260 (20
and 200 mg/kg) groups. (C) The liver weight (LW) to body weight (BW) ratio was
calculated. (D) Serum ALT and (E) AST levels (U/L) were measured (n=10) using
the Piccolo Xpress chemical analyzer. Real-time PCR experiments were
performed to measure the hepatic expression of (F) TGFβ, (G) Collagen1α1 and
(H) TIMP-1, n=10. Values are mean ± SEM, p <0.05, a- ∆ due to HFD, b- ∆ due
to Aroclor 1260 exposure at 20 mg/kg. CD-control diet, HFD-high fat diet, ArAroclor 1260, PV-portal vein, CV-central vein. Figure adapted from Wahlang et
al., Toxicol Appl Pharmacol, 279 (3), 2014.
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Figure 2.4. Effects of Aroclor 1260 exposure on hepatic cholesterol and
triglycerides.
Hepatic levels of (A) cholesterol and (B) triglycerides were quantified
(µg/mg tissue) in mice (n=5) fed with CD or HFD with or without Aroclor 1260 coexposure. Values are mean ± SEM, p <0.05, a- ∆ due to HFD. CD-control diet,
HFD-high fat diet, Ar-Aroclor 1260. Figure adapted from Wahlang et al., Toxicol
Appl Pharmacol, 279 (3), 2014.
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Effects of Aroclor 1260 exposure on serum adipo-cytokines
HFD consumption alone did not increase serum interleukin 6 (IL-6) or
tissue plasminogen activator inhibitor (tPAI-1) levels vs. CD (Fig. 2.5 A&B).
However, HFD-fed mice exposed to Aroclor 1260 at 20 mg/kg displayed
significantly elevated serum IL-6 and tPAI-1 levels (p <0.05). This exposurerelated elevation in pro-inflammatory cytokines was absent in CD-fed mice. In
contrast to the lower exposure, Aroclor 1260 at 200 mg/kg did not increase
serum IL-6 or tPAI-1 levels in either the HFD or CD groups even though
histological examinations indicated higher levels of hepatic macrophage
infiltration in HFD fed animals. Serum tumor necrosis factor alpha (TNFα) and
monocyte chemo attractant protein-1 (MCP1) levels were not affected by either
diet or Aroclor 1260 exposure (Fig. 2.5 C&D).
All the HFD groups displayed elevated serum leptin levels as compared to
CD groups (Fig. 2.5 E, p <0.05) consistent with the increased adiposity observed
in these groups. Exposure to Aroclor 1260 did not affect leptin levels.
Interestingly, serum adiponectin levels did not differ between any of the groups,
irrespective of the diet type consumed (Fig. 2.5 F), leading to an increased
leptin/adiponectin ratio in HFD-fed animals. Similar to leptin, serum resistin levels
were increased in mice fed HFD (Fig. 2.5 G, p <0.05). Furthermore, Aroclor 1260
at 200 mg/kg decreased serum resistin levels in HFD-fed mice vs. HFD+vehicle
and HFD+Aroclor 1260 (20 mg/kg) groups (p <0.05), indicating a dosedependent interaction between Aroclor 1260 and HFD. In summary, Aroclor 1260
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at the lower dose increased serum pro-inflammatory cytokines in HFD-fed mice,
while the higher dose caused a decrease in serum resistin levels.
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Figure 2. 5. Effects of Aroclor 1260 on serum adipo-cytokines.
Serum (A) IL-6 (pg/mL), (B) tPAI-1 (pg/mL), (C) TNFα (pg/mL), (D) MCP1
(pg/mL), (E) leptin (pg/mL), (F) adiponectin (µg/mL) and (G) resistin (pg/mL)
levels were measured using the Luminex IS 100 system (n=10). Values are
mean ± SEM, p <0.05, a- ∆ due to HFD, b- ∆ due to Aroclor 1260 exposure at 20
mg/kg, c- ∆ due to Aroclor 1260 exposure at 200 mg/kg. CD-control diet, HFDhigh fat diet, Ar-Aroclor 1260. Figure adapted from Wahlang et al., Toxicol Appl
Pharmacol, 279 (3), 2014.
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Effects of Aroclor 1260 on insulin resistance, glucose regulation, and
serum lipids
A glucose tolerance test was performed and HOMA-IR was calculated to
determine if HFD and Aroclor 1260 co-exposure exacerbate HFD-induced insulin
resistance, a common hallmark of NAFLD. HFD feeding increased HOMA-IR and
Aroclor 1260 exposure (200 mg/kg) decreased HOMA-IR in HFD-fed mice (Fig.
2.6 A). The HFD group showed greater area under the curve (AUC) in the
glucose tolerance test than any of the CD groups (Fig. 2.6 B&C). Aroclor 1260
though had no additive effect to dietary manipulation alone. Therefore, while
Aroclor 1260 exposure (200 mg/kg) decreased HOMA-IR, there was no
difference in the AUC. The decrease in HOMA-IR could indicate impaired
glucose-stimulated insulin production with Aroclor 1260 exposure. Fasting blood
glucose levels showed that Aroclor 1260 exposure lowered blood glucose levels
in the CD-fed mice at both the 20 and 200 mg/kg doses but not in HFD-fed mice
(Fig. 2.6 D). This observation is consistent with our earlier study where i.p.
injection of PCB 153 resulted in lowered fasting blood glucose levels in mice fed
CD (48).
HFD feeding resulted in significantly higher mean serum cholesterol and
HDL levels vs. CD feeding (p <0.05). Aroclor 1260 exposure at 20 or 200 mg/kg
did not affect mean cholesterol and HDL levels either in the HFD or CD groups
(Table 3). In contrast, HFD feeding did not increase mean serum LDL levels vs.
CD feeding. However, the HFD+Aroclor 1260 (200 mg/kg) group exhibited
significantly higher mean LDL levels vs. CD+vehicle or CD+Aroclor 1260 (200
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mg/kg). Mean serum triglyceride levels were unchanged irrespective of diet
consumed or level of Aroclor 1260 exposure. In summary, HFD was associated
with insulin resistance and serum hypercholesterolemia, but Aroclor 1260 had no
observable effect on these parameters.
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Figure 2.6.HFD increased insulin resistance, and this was unaffected by
Aroclor 1260 co-exposure.
(A) HOMA-IR was calculated from fasting blood glucose and insulin levels
for all six groups of animals (n=10). (B) Glucose tolerance test was performed,
and blood glucose levels were measured for mice (n=10) fed with CD or HFD,
with or without Aroclor 1260 co-exposure. AUC was calculated (C), and the HFD
groups showed higher AUC levels than the CD groups. (D) Fasting blood glucose
levels (mg/dL) were measured, and the CD-fed mice co-exposed to Aroclor 1260
showed lower levels vs. CD+vehicle.Values are mean ± SEM, p <0.05, a- ∆ due
to HFD, b- ∆ due to Aroclor 1260 exposure at 20 mg/kg, c- ∆ due to Aroclor 1260
exposure at 200 mg/kg. CD-control diet, HFD-high fat diet, Ar-Aroclor 1260.
Figure adapted from Wahlang et al., Toxicol Appl Pharmacol, 279 (3), 2014.
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Cholesterol

HDL

LDL

Triglycerides

CD

70.1 ± 7.7

49.1 ± 6.1

12.3 ± 1.7

44.1 ± 6.1

CD+Ar
(20 mg/kg)

76.0 ± 3.9

52.2 ± 3.0

16.1 ± 1.3

40.2 ± 3.6

CD+Ar
(200 mg/kg)

76.8 ± 3.8

56.0 ± 3.0

12.0 ± 1.6

43.8 ± 6.3

HFD

122.1 ± 11.4a

96.8 ± 9.8a

17.3 ± 1.8

38.6 ± 3.1

HFD+Ar
(20 mg/kg)

130.4 ± 8.2a

92.2 ± 4.4a

15.5 ± 2.3

53.0 ± 3.3

HFD+Ar (200
mg/kg)

130.0 ± 5.3a

93.1 ± 2.7a

21.8 ± 1.4c

50.0 ± 3.1

Table 3. Serum levels of cholesterol, high density lipoproteins, low density
lipoproteins and triglycerides.
Values are mean ± SEM (mg/dL), p <0.05, a- ∆ due to HFD, b- ∆ due to
Aroclor 1260 exposure at 20 mg/kg, c- ∆ due to Aroclor 1260 exposure at 200
mg/kg. CD-control diet, HFD-high fat diet, Ar-Aroclor 1260, HDL-high density
lipoproteins, LDL-low density lipoproteins. Table adapted from Wahlang et al.,
Toxicol Appl Pharmacol, 279 (3), 2014.
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Aroclor 1260 exposure modulated hepatic fat metabolism
Liver-X-receptor (LXR) is the key transcription factor that drives lipid
synthesis and cholesterol metabolism and its over-activation can promote or
worsen steatosis (93). We were interested in evaluating if Aroclor 1260 exposure
would increase LXR target gene expression, which in turn, worsens steatosis
caused by HFD. There are similarities in the response elements, to which LXR
and the receptors that PCBs activate (CAR and PXR), bind to. All three receptors
have the capacity to bind direct repeats (DR-4) response elements suggesting
that some degree of crosstalk may be possible. HFD feeding did not alter FAS
hepatic expression vs. CD feeding (Fig. 2.7 A). However, Aroclor 1260 exposure
at 20 and 200 mg/kg decreased FAS hepatic expression in HFD-fed mice (p
<0.05). HFD feeding increased SCD1 hepatic expression (Fig. 2.7 B, p <0.05)
and this result was not affected by Aroclor 1260 exposure. Interestingly, HFD
feeding alone decreased SREBP-1c mRNA levels but co-exposure to HFD and
Aroclor 1260 at both doses resulted in increased SREBP1-c mRNA levels (Fig.
2.7 C, p <0.05), suggesting an interaction between HFD and Aroclor 1260
exposure. Aroclor 1260 exposure at both doses had no effect on SREBP-1c
hepatic expression in CD-fed mice. In contrast, Aroclor 1260 exposure at 20
mg/kg resulted in hepatic upregulation of CD36 in CD-fed mice (Fig. 2.7 D, p
<0.05). Notably, CD36 is an LXR target gene shared by PXR as well (94). In
summary, Aroclor 1260 exposure did not increase FAS or SCD1 hepatic
expression, suggesting that LXR was not activated by the exposure but that
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these genes’ expression may have been modulated by CAR or PXR directly or
indirectly.
PPARα is a transcription factor for lipid-catabolizing genes including
CPT1A, CPT2 and Cyp4b10. PPARα activation results in hepatic lipid oxidation
and may be protective against steatosis. We measured the hepatic expression of
PPARα as well as its target genes, Cyp4b10 and CPT1A (Fig. 2.8 A, B&C). The
mRNA levels of PPARα and Cyp4b10 did not differ between any of the groups
examined. However, CPT1A expression was significantly induced with low dose
Aroclor 1260 exposure in the HFD group vs. HFD alone. Therefore, Aroclor 1260
exposure at 20 mg/kg appeared to induce CPT1A in a HFD-setting by
mechanisms independent of direct PPARα interaction.
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Figure 2.7. Effects of Aroclor 1260 exposure on genes involved in lipid
metabolism.
Real-time PCR experiments showed the changes in hepatic mRNA
expressions caused by Aroclor 1260 exposure for (A) FAS, (B) SCD1, (C)
SREBP-1c and (D) CD36. Values are mean ± SEM, p <0.05, a- ∆ due to HFD, b∆ due to Aroclor 1260 exposure at 20 mg/kg, c- ∆ due to Aroclor 1260 exposure
at 200 mg/kg. CD-control diet, HFD-high fat diet, Ar-Aroclor 1260. Figure adapted
from Wahlang et al., Toxicol Appl Pharmacol, 279 (3), 2014.
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Figure 2.8. Effects of Aroclor 1260 exposure on genes involved in lipid
oxidation.
Real-time PCR experiments showed the changes in hepatic mRNA
expressions caused by Aroclor 1260 exposure for of (A) Cyp4a10 (B) CPT1A
and (C) PPARα. Values are mean ± SEM, p <0.05, b- ∆ due to Aroclor 1260
exposure at 20 mg/kg. CD-control diet, HFD-high fat diet, Ar-Aroclor 1260. Figure
adapted from Wahlang et al., Toxicol Appl Pharmacol, 279 (3), 2014.
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Hepatic expression of TLR-4 target genes
Toll like receptor 4 (TLR-4) activation results in nuclear factor kappa-B
(NF-κB) activation which in turn causes upregulation of pro-inflammatory
cytokines (95). We hypothesized that Aroclor 1260 may interact directly or
indirectly with TLR-4, resulting in monocytic infiltration as observed in liver
histology and increased serum cytokine levels. We therefore measured the
hepatic expression of TLR-4 target genes namely TNFα and IL-6. HFD alone did
not increase TNFα mRNA levels (Fig. 2.9 A). However, exposure to Aroclor 1260
at 20 mg/kg increased TNFα mRNA levels in HFD-fed mice (p <0.05). Aroclor
1260 exposure at 200 mg/kg did not increase TNFα hepatic expression in either
the CD- or HFD-fed mice. Aroclor 1260 exposure at 20 mg/kg in CD fed mice
resulted in increased IL-6 mRNA levels vs. CD alone (Fig. 2.9 B). Aroclor 1260
exposure at 200 mg/kg did not increase IL-6 mRNA levels in either the CD- or
HFD-fed mice. Clearly, Aroclor 1260 exposure at 20 mg/kg led to increased
TNFα and IL-6 hepatic expressions with either HFD or CD respectively. Neither
HFD feeding nor Aroclor 1260 exposure had any effect on MCP2 mRNA levels
whereas MIP1α mRNA levels was increased only with HFD feeding (Fig. 2.9
C&D). These results appear broadly consistent with the serum cytokine levels
data, suggesting increased inflammation and possibly sensitization to TNFαdependent cell death only at the lower dose of Aroclor 1260 (20mg/kg).
Furthermore, the results also suggest that cytokine production may be inhibited
at higher concentrations of Aroclor 1260 (200 mg/kg) by other mechanisms.
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Figure 2.9. Effects of Aroclor 1260 exposure on TLR-4 target genes.
Real-time PCR experiments showed the changes in hepatic mRNA
expressions caused by Aroclor 1260 exposure for (A) TNFα, (B) IL-6, (C) MCP2
and (D) MIP1α. Values are mean ± SEM, p <0.05, a- ∆ due to HFD, b- ∆ due to
Aroclor 1260 exposure at 20 mg/kg. CD-control diet, HFD-high fat diet, Ar-Aroclor
1260. Figure adapted from Wahlang et al., Toxicol Appl Pharmacol, 279 (3),
2014.
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Aroclor 1260 induced hepatic CAR, PXR and AhR target genes
PCBs are known activators of AhR and CAR, which are involved in
xenobiotic detoxification (24, 96). Recent studies have demonstrated PCBs’
interaction with other nuclear receptors including human PXR and rodent
peroxisome-proliferator activated receptor alpha (PPARα) (97-99). We
hypothesized that Aroclor 1260 may interact with these receptors in our animal
model. We therefore looked at the hepatic expression levels of these receptors’
target genes in all animal groups.
The mRNA levels of Cyp2b10, a CAR target gene, were significantly upregulated in all Aroclor 1260-exposed groups (Fig. 2.10 A, p <0.05). In the CD
groups, the fold induction of Cyp2b10 was slightly higher in the lower dose (20
mg/kg) as compared to the higher dose (200 mg/kg) (approximately 1000-fold vs.
500-fold respectively). Feeding a HFD markedly reduced the fold induction of
Cyp2b10 with inductions of 4.3-fold and 12-fold being observed at 20 mg/kg and
200 mg/kg exposures, respectively. Thus the reduction in fold induction caused
by HFD feeding vs. CD feeding at 20 mg/kg and 200 mg/kg was reduced by
approximately 235-fold and 41-fold, respectively. These results appear consistent
with previous studies (100, 101), and indicate that the ability of CAR to activate
target genes is compromised when animals are fed with HFD.
Hepatic Cyp3a11 (PXR target gene) expression levels were also
significantly induced in all Aroclor 1260-exposed groups (Fig. 2.10 B, p <0.05).
The Cyp3a11 fold induction caused by Aroclor 1260 exposure was significantly
lower compared to Cyp2b10 (approximately 30- to 34-fold for the 20 mg/kg
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exposure and 20- to 25-fold for the 200 mg/kg exposure). Contrary to Cyp2b10
expression, HFD did not affect the fold inducibility of this particular gene.
However, HFD feeding decreased the basal expression level of Cyp3a11 by
approximately 8-fold.
The mRNA levels of Cyp1a2 (AhR target gene) were also measured in all
the groups to determine Aroclor 1260 activation of the AhR. Hepatic Cyp1a2
expression was up-regulated in both dietary groups exposed to Aroclor 1260 only
at 200 mg/kg (Fig. 2.10 C, p <0.05) but not at 20 mg/kg. Feeding with a HFD had
no effect on either fold inducibility or basal level expression of this gene. These
results suggest that with Aroclor 1260, the levels of congeners that activate
CAR/PXR are present in much higher concentrations than those that activate
AhR and the receptor based-effects of Aroclor 1260 at the lower dose are likely
to be mediated primarily through CAR/PXR activation.
In addition to direct targets, both CAR and PXR are capable of binding,
potentially sequestering and altering the transcriptional activity of the
transcription factor forkhead box O1 (FOXO1) (74). FOXO1 is an important
transcription factor controlling the expression of a wide range of gluconeogenic
and lipogenic genes. To examine if FOXO1 mediated gene transcription was
being affected, we examined the effects of Aroclor exposure on PEPCK-1, a
prototypical FOXO1 target gene and the rate limiting step in gluconeogenesis.
HFD feeding did not affect PEPCK-1 mRNA levels alone but Aroclor 1260
exposure at 20 mg/kg significantly reduced it in the HFD group (Fig. 2.10 D).
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Figure 2.10. Aroclor 1260 exposure altered hepatic expression of CAR, PXR
and AhR target genes.
Real-time PCR experiments showed the changes in hepatic mRNA
expressions caused by Aroclor 1260 exposure for (A) Cyp2b10 (CAR target
gene), (B) Cyp3a11 (PXR target gene), (C) Cyp1a2 (AhR target gene) and (D)
PEPCK-1 (an indirect target of CAR and PXR). Values are mean ± SEM, p
<0.05, a- ∆ due to HFD, b- ∆ due to Aroclor 1260 exposure at 20 mg/kg, c- ∆ due
to Aroclor 1260 exposure at 200 mg/kg. CD-control diet, HFD-high fat diet, ArAroclor 1260. Figure adapted from Wahlang et al., Toxicol Appl Pharmacol, 279
(3), 2014.
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DISCUSSION
Although several PCB mixtures were commercially produced and used
widely (e.g. Aroclor(s) 1260, 1254, 1248, 1242 and 1016), Aroclor 1260 was
selected for this study because of the similarity in its congener composition
pattern to that in human fat (36). The major congeners in Aroclor 1260 are the
high molecular weight PCBs that have either 5-, 6-, 7- or 8- chlorine substituents,
which in turn results in di-ortho substitution, and hence are non-coplanar in
structure. These high molecular weight PCBs are not well metabolized and
therefore bio-accumulate in humans (35). PCB toxicity has been associated with
cancer, endocrine disruption, and impaired cognitive development, but recent
epidemiologic studies have shown that PCB exposures can also result in
metabolic disorders associated with NAFLD, including obesity, insulin
resistance/diabetes, and the metabolic syndrome (41, 42, 102). Occupational
exposure to PCB mixtures has also been associated with elevated plasma levels
of liver enzymes (18). Chronic exposures to these chlorinated compounds
appear to disrupt both lipid and glucose homeostasis and consequently lead to
diabetes and associated metabolic disorders. The current study investigated the
effects of environmental pollutant-nutrient interactions, which is clinically relevant
because all humans are exposed to PCBs and over 75% of the US adult
population is considered to be either overweight or obese. Exposure to toxicants
such as PCBs may act as a ‘second hit’ that eventually drives this population to
steatohepatitis and the metabolic syndrome.
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PCBs bio-accumulate in the liver and adipose tissue due to their
hydrophobicity, thus, making these sites principal targets for PCB toxicity. Lipidadjusted serum PCB levels were measured in NHANES participants and in the
PCB exposed Anniston cohort with the highest reported levels ranged from 75170 ng/g (18, 46). Additionally, the National Toxicology Program (NTP) studies
measured PCB levels in a 2-year gavage study in rats. Interestingly, PCB liver
levels were at least 10-fold higher and adipose levels were at least 200-fold
higher than lipid-adjusted serum levels irrespective of the dose administered or
treatment time (22). Although Aroclor 1260 levels were not measured in our
study, we speculate that the distribution will be similar to other PCBs used in
NTP studies. In those studies, a 20 mg/kg cumulative dose yielded the following
levels: serum-176 ng/g, liver-3,663 ng/g and adipose-92,840 ng/g while a 200
mg/kg cumulative dose yielded levels: serum-1,788 ng/g, liver-34,010 ng/g and
adipose-1,118,300 ng/g. Thus the 20 mg/kg dose employed is expected to
produce serum levels similar to the maximum levels reported for the Anniston
cohort (170.4 ng/g). The 200 mg/kg dose is similar to that used in the NTP TR
530 for cancer studies. In the present study, we exposed mice to PCBs using
gavage which was designed to mimic human exposure routes. A potential caveat
is that these mice received either a single exposure or four separate exposures
rather than the intermittent exposures that humans encounter from eating PCBcontaminated food. We also attempted to have several weeks between exposure
to PCBs and the measurement of study endpoints to maximize the effects from
bio-accumulated PCBs rather than any metabolized congeners.
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The main finding from this study was the Aroclor 1260-mediated transition
of steatosis to steatohepatitis in the diet-induced obesity model. Paradoxically,
NASH was associated with decreased % fat composition and increased lean
body mass at the low dose exposure (Fig. 2.2). Additionally, CD groups showed
a decrease in body weight gain which may be attributed to stress experienced
due to oral gavage. None of the CD groups exposed to Aroclor 1260 manifested
hepatitis (H&E staining). Contrarily, Aroclor 1260 exposure in HFD groups
worsened liver necro-inflammation (Fig. 2.3). Co-exposure to HFD and Aroclor
1260 (20 mg/kg) resulted in elevated serum ALT, IL-6 and tPAI-1 and
upregulated hepatic TNFα expression (Fig. 2.5). However, Aroclor 1260 at 200
mg/kg did not induce systemic inflammation, despite histologic signs of liver
injury.
The results from this study differed markedly from our earlier work on a
single congener, PCB 153, where HFD+PCB 153 co-exposure worsened
steatosis and obesity in male C57Bl/6J mice without causing inflammation (48).
We documented PCB 153-mediated adipokine dysregulation; a phenomenon
which was absent in the current study. Furthermore, HFD+PCB 153 co-exposure
altered hepatic expression of genes involved in fatty acid metabolism including
increased FAS and decreased CPT1A mRNA expression. Although PCB 153 is
present in Aroclor 1260, other congeners are present in this PCB mixture that
may contribute to steatohepatitis and yet have no effect on obesity. Thus,
exposing animals to a mixture can yield outcomes that are entirely different from
that of a single congener.
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Hepatic P450s, including Cyp3a11 (PXR target) and Cyp2b10 (CAR
target), were induced by Aroclor 1260 exposure in both CD and HFD-fed mice
(Fig. 2.10). PXR and CAR are critically involved in xenobiotic metabolism and
drug disposition, but recent studies demonstrated the importance of CAR and
PXR regulation on physiological processes such as glucose and lipid
metabolism, and this could impact NASH (60, 103, 104). Gao et al. demonstrated
CAR as an anti-obesity receptor whose activation was protective against dietinduced obesity and insulin resistance (72). On the contrary, the role of PXR in
obesity remains controversial with studies reporting either anti-obesity or obesity
promoting effects (75, 77, 105). Our RT-PCR data strongly suggest CAR
activation by Aroclor 1260 as indicated by the ~1000- to 500-fold induction of
Cyp2b10 at both the low and high exposure levels. Cyp3a11 induction is a
hallmark of PXR activation, but activated CAR can also bind to the Cyp3a11
response element and drive its expression, albeit, at lower levels. Although
Cyp3a11 was induced by ~30-fold, this induction may be mediated by CAR
rather than PXR. These results indicate that Aroclor 1260 exposure activated
CAR/PXR, hence the possible obesity-protective effects seen in the HFD-fed
mice exposed to Aroclor 1260.
Furthermore, CAR/PXR activation suppresses FOXO1-insulin response
sequence (IRS) binding activity (Kodama et al., 2004) resulting in decreased
gluconeogenesis and hence the lowered fasting blood glucose levels seen in
CD+Aroclor 1260 groups (Fig. 2.6). Additionally, FOXO1, is a negative regulator
of SREBP1 transcription and its sequestration by activated CAR/PXR could

65

result in increased SREBP1 gene expression (74, 106). Notably in our study,
hepatic SREBP-1c expression was induced in HFD-fed mice exposed to Aroclor
1260. However, activated CAR and PXR can transcriptionally activate the antilipogenic gene Insig, consequently leading to reduced SREBP1 activity and
decreased SREBP1 target gene expression such as FAS (73). Hence, the
decrease in FAS expression observed in this study could possibly be due to loss
of SREBP1 activity even though the gene was induced. Additionally, CD36, a
lipid scavenger receptor and target gene shared by AhR, PXR and LXR was also
induced by Aroclor 1260 (Fig. 2.7). Other novel findings in this study included
induction of CPT1A and decreased hepatic FAS expression with Aroclor 1260
exposure in HFD-fed mice. In concert, the effects of Aroclor 1260 on lipogenesis
appeared complex, and interactions with CAR/PXR could contribute to the
observed decrease in % fat composition in HFD+Aroclor 1260 groups. Moreover,
glucose metabolism was abnormal in HFD-fed mice exposed to Aroclor 1260
(200 mg/kg), because, while HOMA-IR was lowered, glucose tolerance failed to
improve. It appears that HOMA-IR and glucose tolerance test may be insufficient
to evaluate glucose metabolism in PCB studies, given the partially divergent
effects of PCB exposure in the fed and fasted state. However, these
observations need to be pursued further to elucidate the mechanisms involved.
Regardless of Aroclor 1260 exposure, it appeared that HFD consumption
reduced the induction of CAR/PXR target genes as compared to CD
consumption and it was only HFD-fed mice exposed to Aroclor 1260 that
exhibited liver injury. Therefore, it is plausible to say that activation of xenobiotic
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receptors such as CAR/PXR protect against PCB toxicity in a low fat diet setting.
Therefore HFD consumption interferes with CAR/PXR activation by PCBs, and
therefore attenuates the protective effects of these receptors against PCB toxicity
with the net result being increased liver injury only in Aroclor 1260+HFD coexposed animals. The progression of NAFLD from simple steatosis to
steatohepatitis requires both hepatic fat accumulation and inflammation. In this
study, it was observed that in steatotic mice exposed to low dose Aroclor 1260,
inflammation and liver injury was aggravated, while at the high dose,
inflammation was suppressed and liver injury was attenuated. Our results
suggest that it is the inflammatory dysfunction that PCBs induce rather than the
degree of steatosis observed that may dictate appearance of steatohepatitis.
Hepatic expression of Cyp1a2 (AhR target gene) was induced only in
groups receiving Aroclor 1260 at the highest dose tested (Fig. 2.10), suggesting
dose-dependent activation of this receptor. AhR activation by PCBs is well
documented with coplanar (‘dioxin-like’) PCBs including PCB 126 being good
rodent AhR activators. A wasting syndrome and chloracne are characteristic
features of AhR activation by its classic ligand TCDD (107). AhR activation is
also associated with immune suppression via AhR interference with NF-κB
signaling (108). Consistent with these results, animals exposed to Aroclor 1260
(200 mg/kg) displayed lower body weight and a suppression of serum proinflammatory cytokines and resistin levels (Fig. 2.5). Resistin, also known as the
adipocyte secretory factor, is secreted by the adipose tissue and appears to
participate in inflammatory processes as well (109). While reduced body weight
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has frequently been reported with animals exposed to AhR ligands, in murine
and human models, steatosis increases, presumably due to a redistribution of
dietary fat (110). Thus activation of the AhR may lead to increased steatosis but
decreased steatohepatitis, as a function of its immunosuppressive effects. The
activation AhR by Aroclor 1260 is likely due to the presence of coplanar
congeners such as PCB 126 but these compounds exist in relatively low
percentages in this mixture (<1%), and hence a higher Aroclor 1260 exposure
level is required to observe the ‘dioxin-like’ effects. Therefore, absence of
inflammation at the higher dose may be due to the immune-suppressive
properties of activated AhR.
Thus, we identified both CAR/PXR and AhR activation as potential
mode(s) of action of this PCB mixture in NASH. Nonetheless, rodent and human
receptors may have differences pertaining to ligand binding activity and target
gene battery. Off target effects are also possible mechanisms in PCB-driven
NASH, but these were not evaluated in this study. Moreover, the current study
failed to distinguish between CAR and PXR activation which is a potential
drawback since the observed Aroclor 1260 effects may be based solely on CAR
activation. Thus further investigation to distinguish between the CAR an d PXRmediated effects using PXR/CAR knockout models is required. The study also
failed to assess overall metabolism and employing metabolic chambers would
have been useful in this regard. Furthermore, another drawback in this study was
using serum ALT/AST as a NASH biomarker based on low sensitivity, and
evaluating other biomarkers is a possibility in future studies (50). In addition, our
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studies were performed using male mice; hence it is pertinent to note that the
observed effects may vary with gender and species.
In conclusion, Aroclor 1260 exposure caused toxicant-associated
steatohepatitis in animals fed with HFD. In contrast to our previous study wherein
a single congener (PCB 153) was used, this PCB mixture neither increased the
body weight/visceral adiposity nor worsened insulin resistance/diet-induced
obesity. There was a significant difference between the low and high exposure
doses in terms of hepatic/systemic inflammation, which could potentially be due
to AhR activation. Our additional findings demonstrate that Aroclor 1260
activated CAR and PXR and to a lesser extent AhR, suggesting congener
composition and exposure levels to be critical in determining a mixture’s mode(s)
of actions. Lastly, CAR and PXR activation could be protective against PCBmediated toxicity but HFD consumption may blunt this protection. More studies
are needed on the role of PCB-nuclear receptor interactions in steatohepatitis.
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CHAPTER 3
EVALUATING THE ROLE OF CAR AND PXR IN AROCLOR 1260-INDUCED
LIVER INJURY
INTRODUCTION
Our initial studies in a diet-induced obesity mouse model demonstrated
that Aroclor 1260 exposure had modest effects on a control diet but induced
steatohepatitis when animals were fed with a high fat diet. In animals fed a high
fat diet, Aroclor 1260 exposure did not exacerbate obesity. However, in the liver,
Aroclor 1260 exposure (20 mg/kg) activated nuclear receptors, including CAR
and PXR as the cytochrome P450s, namely, Cyp2b10 and Cyp3a11 were
robustly induced. At higher Aroclor 1260 exposures (200 mg/kg), the AhR was
also activated. Furthermore, PCB activation of the AhR has been well studied
and its activation has been linked to hepatic cancer. However PCB activation of
CAR and PXR and the subsequent contribution of these activated receptors to
PCB effects and toxicity have not been thoroughly evaluated, especially in terms
of obesity and NAFLD/NASH.
In this study, the role of CAR and PXR in Aroclor 1260-induced liver injury
was further characterized. We hypothesized that CAR and PXR play a role in the
transition of steatosis to steatohepatitis caused by Aroclor 1260 exposure. The
CAR and PXR knockout mouse models were utilized to demonstrate that both
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receptors were required for normal physiology and that they both played a
protective role in PCB+HFD-induced liver disease. Additionally, in the previous
study, mice receiving Aroclor 1260 at 20 mg/kg elicited CAR and PXR activation
as well as NASH; therefore this dose was employed again in the present study.
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MATERIALS AND METHODS
Animals and diets
The animal protocol was approved by the University of Louisville
Institutional Animal Care and Use Committee. Wild type male C57Bl/6J mice
(WT, 8 weeks old; The Jackson Laboratory, Bar Harbor, ME, USA) and CAR-/and PXR-/- mice (Taconic, Hudson, NY) were divided into 6 study groups (n=10)
based on Aroclor 1260 exposure utilizing a 2x3 design. All mice were fed a high
fat diet (HFD, 42% kCal from fat; TD.88137 Harlan Teklad) in this 12 week study.
On Week 1, Aroclor 1260 (AccuStandard, CT, USA) was administered in corn oil
by oral gavage (vs. corn oil alone) at 20 mg/kg. This dose was designed to mimic
the maximum human PCB exposures seen in the PCB-exposed Anniston cohort.
Mice were housed in a temperature- and light controlled-room (12 hour light; 12
hour dark) with food and water ad libitum. During Week 8-9, mice were placed in
metabolic chambers (PhenoMaster, TSE systems, Chesterfield, MO) overnight to
assess food/drink consumption and physical activity. A glucose tolerance test
was performed at Week 11, and the animals were euthanized (ketamine/
xylazine, 100/20 mg/kg body weight, i.p.) at the end of Week 12. Prior to
euthanasia, the animals were analyzed for body fat composition by dual energy
X-ray absorptiometry (DEXA) scanning (Lunar PIXImus densitometer, WI, USA).
Thus six different groups were evaluated; WT, WT+Aroclor 1260, CAR-/-, CAR-/+Aroclor 1260, PXR-/-, PXR-/-+Aroclor 1260.
Glucose tolerance test
See detailed method in Chapter 2.
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Histological studies
See detailed method in Chapter 2.
Cytokine and adipokine measurement
See detailed method in Chapter 2.
Measurement of hepatic triglyceride and cholesterol content
See detailed method in Chapter 2.
Real-time PCR
See detailed method in Chapter 2. Additional primer sequences from
Taqman Gene Expression Assays (Applied Biosystems, Foster City, CA) that
were utilized in the current study included UDP glucuronosyltransferase 1 family,
polypeptide A1 (Ugt1a1); (Mm02603337_m1), patatin-like phospholipase domain
containing 2 (PNPLA2); (Mm00503040_m1), PXR (Mm01344139_m1), CAR
(Mm01283978_m1), fatty acid binding protein-1 (FABP1); (Mm00444340_m1),
glucokinase (Gck); (Mm00439129_m1), GLUT-2, (Mm00446229_m1), GLUT-4
(Mm01245502_m1), glucose-6-phosphatase (G6Pase); (Mm00839363_m1),
Insig-1 (Mm00463389_m1) and Insig-2 (Mm01308255_m1).
Immunoblots
Frozen liver samples (0.1 g) were homogenized in 0.5 mL radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1
mM EDTA, 1 mM EGTA, 1 mM β-glycerophosphate, 1 mM sodium vanadate, and
1% w/w Triton X-100 w/v) containing 1 mM phenylmethylsulphonyl fluoride,
protease and phosphatase (tyrosine and serine/threonine) inhibitor cocktails
(Sigma Aldrich, St. Louis, MO, USA). Lysates were sonicated at 4 °C for 4 h and
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subsequently centrifuged for 5 minutes at 16,000 g. The protein concentration of
the supernatants was determined using the Bicinchoninic Acid Protein Assay Kit
(Sigma Aldrich). Total protein was diluted in RIPA buffer and mixed with sample
loading buffer [250 mM Tris, pH 7.4, 10% sodium dodecyl sulfate (SDS), 20% βmercaptoethanol w/v, 40% glycerol, and 0.05% bromophenol blue] and incubated
at 95 °C for 5 minutes. The samples were loaded onto SDS-polyacrylamide gels
(Bio-Rad Laboratories, Hercules, CA, USA), followed by electrophoresis and
Western blotting onto polyvinylidene difluoridemembranes (Immobilon-P;
Millipore Corp, Billerica, MA, USA). Antibodies against the sterol regulatory
element binding protein 1 (SREBP1, Abcam, Cambridge, MA, USA), AMPactivated protein kinase α (AMPKα, Cell Signaling Technology, Danvers, MA,
USA), phospho-AMPKα (p-AMPKα, Cell Signaling Technology), mammalian
target of rapamycin (mTOR, Cell Signaling Technology), phospho-mTOR (pmTOR, Cell Signaling Technology) and β-actin (Santa Cruz Biotechnology,
Dallas, TX, USA) were used at dilutions recommended by the suppliers.
Horseradish peroxidase-coupled secondary antibodies were obtained from
Abcam and Cell Signaling Technology. Chemiluminescence detection was
performed using the Pierce ECL2 western blotting substrate reagents (Thermo
Scientific, Wilmington, DE, USA). Densitometric quantitation was performed with
the Image Lab software (Bio-Rad Laboratories).
Statistical Analysis
Statistical analyses were performed using SigmaPlot version 11.0 (Systat
Software, Inc., San Hose, CA, USA). Data are expressed as mean ± SEM.
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Multiple group data were compared using Two Way ANOVA followed by Tukey
Test for post-hoc all pairwise comparisons. P <0.05 was considered statistically
significant.

75

RESULTS
Effects of CAR and PXR on bodyweight and adiposity
Bodyweight was measured weekly throughout the 12-week study (Fig. 3.1
A). All groups experienced bodyweight gain until Week 11. The bodyweight drop
was possibly due to stress caused by the glucose tolerance test that was
performed on Week 11. Aroclor 1260 exposure had no significant effect on the
percent (%) increase in bodyweight gain calculated in the WT or PXR-/- groups
(Fig. 3.1 B). However, the CAR-/- mice exposed to Aroclor 1260 showed a lower
% increase in the bodyweight gain than any other group. The % body fat
composition was evaluated by DEXA scanning prior to harvesting the tissues
(Fig. 3.1 C). Because all groups were on HFD feeding, the average % body fat
composition among the animals was ~40%. However, the PXR-/- groups
displayed significantly higher % body fat composition with or without Aroclor 1260
exposure. The PXR-/- groups also showed significantly lower lean body mass (g),
irrespective of Aroclor 1260 exposure (Fig. 3.1 D). The liver to bodyweight ratio
(LW/BW) was calculated and the PXR-/- groups showed significantly higher liver
mass and LW/BW when compared to any other group (Fig. 3.1 E).
The epididymal fat sections were stained with H&E (Fig. 3.2 A) and the
adipocyte size was measured using Image J software (Fig. 3.2 B). The mean
adipocyte size (µm2) was lower in the CAR-/- groups irrespective of Aroclor 1260
exposure. There was no difference in the adipocyte size in the WT or PXR-/- mice
irrespective of Aroclor 1260 exposure. Ad libitum food consumption per mouse
per day (g) was calculated over the 12-week period of the study (Fig. 3.2 C).
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There was a drop in the food consumption rate on Week 2 for all groups possibly
due to the corn oil gavage. During the study period, the CAR-/- and PXR-/- mice
exposed to Aroclor 1260 showed relatively lower food consumption rate while the
WT groups showed higher food consumption rate with or without Aroclor 1260
exposure.
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Figure 3.1. Effects of Aroclor 1260 exposure on body weight and visceral
adiposity in CAR-/- and PXR-/- mice.
(A) Increase in body weight with time for C57BL/6 (WT), CAR-/- and PXR-/mice (n=10) fed with a 42% milk fat diet. Body weight measurements were taken
weekly from Week 1 to Week 12. (B) The % increase in body weight gain with
time was calculated and the body weight at Week 1 was taken as 100%. (C) %
fat composition and (D) lean tissue mass (g) were measured using the DEXA
scanner. PXR knockout mice demonstrated a higher % fat composition and
lowered lean tissue mass vs. WT and CAR-/- groups. (E) Livers were removed
and weighed at euthanasia and the liver to bodyweight ratio was calculated.
Values are mean ± SEM, p <0.05, *- ∆ due to Aroclor 1260 exposure, # - ∆ due
to knocking out CAR or PXR.
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Figure 3.2. Effects of Aroclor 1260 exposure on the adipocyte size and food
consumption in CAR-/- and PXR-/- mice.
(A) The epididymal adipose tissue was stained with H&E. (B) Adipocyte
size (µm2) was measured and average cell size of >100 cells for each group was
calculated. (C) Food consumption per mouse per day (g) was measured
throughout the 12 week period. Values are mean ± SEM, p <0.05, * - ∆ due to
Aroclor 1260 exposure, # - ∆ due to knocking out CAR or PXR.
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Metabolic chamber studies
Animals were placed in metabolic cages at the beginning of Week 8 for
metabolic assessment. Oxygen consumption (vO2) and carbon dioxide
production (vCO2) were monitored and the respiration exchange rate (RER,
vCO2/vO2) was calculated. The measured ratio (RER) was used to estimate the
respiratory quotient which indicates whether the fuel source/energy expenditure
is from carbohydrate or lipid metabolism. An RER of 0.70 suggests that fat is the
predominant fuel source (oxidation of a molecule of fatty acid: 23 O2 + C16H32O2
→ 16 CO2 + 16 H2O + 129 ATP, RER = vCO2/vO2 = 16 CO2/23 O2 = 0.7),
whereas an RER of 0.85 indicates a mix of fat and carbohydrates. An RER of
1.00 or above is indicative of carbohydrate being the predominant fuel source
(oxidation of a molecule of carbohydrate: 6 O2 + C6H12O6 → 6 CO2 + 6 H2O + 38
ATP, RER = vCO2/vO2 = 6 CO2/6 O2 = 1.0) and this usually occurs during intense
physical activity such as exercise.
The knockout groups that were unexposed to Aroclor 1260 showed a
lower RER (~0.70), indicating a lipid-driven energy breakdown (Fig. 3.3 A). The
RER was increased with Aroclor 1260 exposure in the knockout groups in both
the light and dark cycle, indicating a mix of fat and carbohydrate fuel source.
There was no difference in the RER in WT mice with or without Aroclor 1260
exposure. The total energy expenditure (EE) was computed using the following
modified Weir equation: EE = (3.815 + 1.232 x RER) x VO2 (111). There were no
differences in the EE between the groups (Fig. 3.3 B).
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Movement/physical activity was also assessed using the metabolic
chambers. The CAR and PXR knockout mice exposed to Aroclor 1260 showed
increased movement/physical activity during the light cycle relative to the
unexposed knockout mice (Fig. 3.4 A). Furthermore, the CAR-/- group exposed to
Aroclor 1260 demonstrated significantly lower food and drink consumption in the
dark cycle vs. any other group (Fig. 3.4 B&C).
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Figure 3.3. Assessment of respiration exchange rate and energy
expenditure utilizing metabolic cages.
Four mice from each group were taken randomly and placed in metabolic
cages for 24 h (12 h light and 12 h dark cycle). (A) The respiration exchange rate
(RER) which is the ratio of CO2 exhaled to O2 consumed was calculated as an
indicator of energy expenditure. (B) The total energy expenditure (EE, kCal/kg/h)
was calculated using the values obtained from RER and VO2. Values are mean ±
SEM, p <0.05, * - ∆ due to Aroclor 1260 exposure, # - ∆ due to knocking out
CAR or PXR.
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Figure 3.4. Assessment of movement, food and drink consumption utilizing
metabolic cages.
Four mice from each group were taken randomly and placed in metabolic
cages for 24 h (12 h light and 12 h dark cycle). (A) Physical activity was
measured using infrared beams and sensors. The total movement (counts) which
is the sum of ambulatory movement (mouse crosses two adjacent beams) and
fine movement (mouse crosses the same beam twice) was calculated. The
average amount of (B) food (g)/day and (C) water (mL)/day consumed per group
was measured. Values are mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260
exposure, # - ∆ due to knocking out CAR or PXR, Ar-Aroclor 1260.
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The role of CAR and PXR in Aroclor 1260-induced liver injury and steatosis
All animal groups developed steatosis by the end of the study due to high
fat feeding. Histological examination of liver sections demonstrated that Aroclor
1260 exposure induced liver injury in all groups of mice and this injury was
independent of the presence of CAR or PXR (Fig. 3.5 A). Scattered inflammatory
foci and neutrophil infiltration were also observed with CAE staining and these
foci were more pronounced in the PXR-/- mice exposed to Aroclor 1260 (Fig. 3.5
B). Although exposure to Aroclor 1260 caused liver injury (H&E and CAE
staining), serum ALT was not significantly elevated (Fig. 3.5 C). Furthermore,
serum AST was unaffected in all groups (Fig. 3.5 D).
Hepatic levels of triglycerides and cholesterol were quantified to measure
the degree of steatosis and there were no significant differences in hepatic lipids
among the groups (Fig. 3.5 E&F). This was somewhat surprising as the PXR-/mice had a higher body fat composition and higher liver to body weight ratios.
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Figure 3. 5. Aroclor 1260 exposure caused steatohepatitis in WT, CAR-/- and
PXR-/- mice.
(A) H&E staining of hepatic sections established the occurrence of
centrilobular hepatocellular hypertrophy, karyomegaly, and multinucleate
hepatocytes in the Aroclor 1260-exposed groups. High fat diet consumption
resulted in variable, centrilobular, microvesicular lipidosis while mice exposed to
Aroclor 1260 exhibited occasional, small areas of necrosis and inflammation
(steatohepatitis). (B) CAE staining demonstrated neutrophil infiltration in the
Aroclor 1260-exposed groups. (C). Serum ALT and (D) AST levels (U/L) were
measured (n=10) using the Piccolo Xpress chemical analyzer. Hepatic levels of
(E) cholesterol and (F) triglycerides were quantified (µg/mg tissue) in mice (n=10)
fed with HFD with or without Aroclor 1260 co-exposure. Values are mean ± SEM,
p <0.05, * - ∆ due to Aroclor 1260 exposure, # - ∆ due to knocking out CAR or
PXR, Ar-Aroclor 1260.
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CAR and PXR are protective against Aroclor 1260-induced hepatic and
systemic inflammation
To further assess the role of nuclear receptors in Aroclor 1260-induced
steatohepatitis, hepatic expression of toll like receptor 4 (TLR-4) target genes
including tumor necrosis factor alpha (TNFα), interleukin 6 (IL-6), monocyte
chemo-attractant protein 2 (MCP2) and monocyte inducible factor 1 alpha
(MIP1α) were measured using RT-PCR. Aroclor 1260 exposure resulted in
increased TNFα expression in the liver of WT mice (Fig. 3.6 A). Interestingly, the
basal expression of TNFα in the knockout mice was higher than in the WT mice,
regardless of Aroclor 1260 exposure. The CAR-/- mice with or without Aroclor
1260 exposure showed significantly higher TNFα mRNA levels when compared
to any other group. Likewise, the basal expression of hepatic IL-6 was also
higher in the knockout groups than the WT group (Fig. 3.6 B). PXR-/- mice
exposed to Aroclor 1260 showed the highest hepatic IL-6 mRNA levels among all
groups. Hepatic expression of MCP2 and MIP1α were not significantly different
between the groups (Fig. 3.6 C&D). Overall, it appeared that knocking out CAR
and PXR increased hepatic TNFα and IL-6 expression, irrespective of Aroclor
1260 exposure.
Serum cytokines, namely, TNFα, IL-2, interferon gamma (IFNγ), IL-17,
MCP1 and MIP-1α were measured using the Luminex IS system. Similar to
hepatic TNFα expression, serum TNFα levels were higher in Aroclor 1260exposed WT-mice compared to unexposed mice in the WT group (Fig. 3.7).
However, there was no significant difference in serum TNFα levels in the Aroclor
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1260-exposed compared to unexposed mice in the knockout groups. Likewise,
serum IL-2 and IFNγ were also increased in the Aroclor 1260-exposed when
compared to unexposed mice in the WT group but there was no difference
observed in the knockout groups. Notably, the basal levels of serum TNFα and
IL-2 were higher in the PXR-/- group, irrespective of Aroclor 1260 exposure. There
was no significant increase in serum IL-17, MIP1α and MCP1 among the groups.
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Figure 3.6. Effects of Aroclor 1260 exposure on the TLR-4 target genes in
CAR-/- and PXR-/- mice.
Real-time PCR experiments showed the changes in hepatic mRNA
expression caused by Aroclor 1260 exposure and knocking out CAR or PXR for
(A) TNFα, (B) IL-6, (C) MCP2 and (D) MIP1α. Values are mean ± SEM, p <0.05,

* - ∆ due to Aroclor 1260 exposure, # - ∆ due to knocking out CAR or PXR.
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Figure 3.7. Effects of Aroclor 1260 exposure on serum cytokines in CAR-/and PXR-/- mice.
Serum TNFα (pg/mL), IL-2 (pg/mL), IFNγ (pg/mL), IL-17 (pg/mL), MIP1α
(pg/mL) and MCP1 (pg/mL) levels were measured using the Luminex IS 100
system (n=10). Values are mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260
exposure, # - ∆ due to knocking out CAR or PXR.
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Aroclor 1260, CAR and PXR regulation in glucose metabolism and insulin
resistance
Fasting blood glucose levels were measured prior to performing the
glucose tolerance test. There were no differences in fasting blood glucose levels
between the six groups (Fig. 3.8 A). Glucose tolerance test was then performed
and the area under the curve (AUC) was calculated to measure the degree of
glucose uptake and clearance in the fed state (Fig. 3.8 B&C). Aroclor 1260
exposure had no effect on GTT (AUC) in WT and CAR-/- groups. In contrast,
Aroclor 1260 exposure caused an increase in the GTT (AUC) in PXR-/- mice.
Insulin resistance was calculated by homeostasis model assessment
using the formula: homeostasis model assessment of insulin resistance (HOMAIR)=Fasting glucose (mg/dL) x Fasting insulin (µU/mL)/405. HOMA-IR was
calculated to determine if CAR and PXR played a role in high fat diet-induced
insulin resistance, a common hallmark of non-alcoholic fatty liver disease (Fig.
3.8 D). Aroclor 1260 exposure significantly decreased HOMA-IR in WT, CAR-/and PXR-/- groups, although fasting blood glucose levels were not decreased.
The reduction in HOMA-IR was due to lower serum insulin levels in all groups
exposed to Aroclor 1260 (Fig. 3.8 E). These results indicated that Aroclor 1260
exposure resulted in impaired insulin production and thus, although GTT (AUC)
was unchanged, HOMA-IR was decreased. Insulin sensitivity was assessed
using the quantitative insulin sensitivity check index (QUICKI) as follows:
QUICKI=1 / (log (fasting insulin µU/mL) + log (fasting glucose mg/dL)).
Interestingly, the Aroclor 1260-exposed, PXR knockout group showed a
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significantly higher index for insulin sensitivity, indicating a significant interaction
between Aroclor 1260 exposure and PXR ablation (Fig. 3.8 F).
Furthermore, to assess gluconeogenesis, the hepatic expression of the
CAR/PXR indirect targets, phosphoenol-pyruvate carboxykinase 1 (PEPCK-1)
and glucose-6-phosphatase (G6Pase) were measured (Fig.3.9 A&B). Hepatic
PEPCK-1 m RNA levels were not affected with Aroclor 1260 exposure in the WT
group. However, Aroclor 1260 exposure in the knockout groups induced PEPCK1 and this induction was highest in the PXR-/- group, which may explain the
increase in fed-state glucose levels as indicated by the GTT (AUC). Additionally,
the PXR knockout mice exposed to Aroclor 1260 also showed significantly higher
G6Pase expression in the liver. These data indicated that the gluconeogenic
pathway was switched on in this group of mice, thus causing an increase in GTT
(AUC).
Hepatic expression of the glycolytic enzyme glucokinase (Gck) was
induced only in the CAR knockout mice exposed to Aroclor 1260 but not in the
WT mice (Fig.3.9 C). This could potentially explain the increase in RER with
Aroclor 1260 exposure in the CAR knockout groups. Hepatic expression of the
glucose transporter GLUT-2 was increased with Aroclor 1260 exposure in the
WT and CAR knockout groups but the induction by Aroclor 1260 was lost in the
PXR knockout group (Fig. 3.9 D). On the other hand, the basal expression of the
insulin-dependent glucose transporter, GLUT4 was higher in the CAR knockout
groups but the mRNA levels were decreased with Aroclor 1260 exposure (Fig.
3.9 E).
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Figure 3.8. Effects of Aroclor 1260, CAR and PXR in glucose metabolism
and insulin resistance.
(A) Fasting blood glucose levels (mg/dL) were measured and (B) glucose
tolerance test was performed. Blood glucose levels were measured for mice
(n=10) fed with high fat diet with or without Aroclor 1260 co-exposure. (C) AUC
was calculated, and the PXR knockout mice exposed to Aroclor 1260 showed
higher AUC levels vs. unexposed group and WT exposed mice. (D) Homeostasis
model assessment of insulin resistance (HOMA-IR) was calculated from fasting
blood glucose and insulin levels for all six groups of animals (n=10). (E) Serum
insulin levels were measured using the Luminex IS 100 system. (F) Quantitative
insulin sensitivity check index (QUICKI) which is an index for insulin sensitivity
was calculated. Values are mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260
exposure, # - ∆ due to knocking out CAR or PXR.
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Figure 3.9. Effects of Aroclor 1260, CAR and PXR on genes involved in
glucose metabolism.
Hepatic (A) PEPCK-1, (B) G6Pase, (C) glucokinase, (D) GLUT-2 and (E)
GLUT-4 mRNA levels were quantified by RT-PCR. Values are mean ± SEM, p
<0.05, * - ∆ due to Aroclor 1260 exposure, # - ∆ due to knocking out CAR or
PXR.
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CAR and PXR ablation altered serum adipokine levels
Serum adipokines were measured to evaluate the effects of knocking out
CAR/PXR on the adipose tissue. Serum leptin levels were not changed with
either Aroclor 1260 exposure or by knocking out CAR/PXR. In contrast, serum
adiponectin levels were increased in the knockout mice, regardless of Aroclor
1260 exposure, leading to a decreased leptin/adiponectin ratio in the knockout
mice (Fig.3. 10 A). This finding was consistent with the decreased adiposity
observed in the CAR knockout group. However, the decreased leptin/adiponectin
ratio was a paradoxical finding in the PXR knockout groups because the mice in
these groups did not show a decrease in adiposity. Serum tissue plasminogen
activator inhibitor-1 (tPAI-1) levels were not changed between the groups (Fig.
3.10 B). Serum lipids were also measured, including cholesterol and triglycerides
(Fig. 3.10 C&D). Serum cholesterol levels were higher in the unexposed, PXR
knockout group whereas serum triglycerides levels were not altered between the
groups.
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Figure 3.10. CAR/PXR knockout mice demonstrated altered serum
adipokine levels.
(A) Serum leptin (pg/mL) and adiponectin (pg/mL) were measured using
the Luminex IS 100 system and the leptin to adiponectin ratio was calculated. (B)
Serum tPAI-1 levels were measured using the Luminex IS 100 system. Serum
(C) cholesterol and (D) triglycerides were quantified with the Piccolo Xpress
chemical analyzer. Values are mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260
exposure, # - ∆ due to knocking out CAR or PXR.
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Aroclor 1260, CAR and PXR modulated hepatic lipid metabolism and
energy expenditure
Liver-X-receptor alpha (LXRα) is a key transcription factor in lipid
synthesis and cholesterol metabolism and its over-activation can promote or
worsen steatosis. In the previous study, we demonstrated that Aroclor 1260
exposure modulated hepatic fat metabolism by either upregulation or
downregulation of genes involved in fatty acid synthesis and breakdown.
Moreover, CAR and PXR can bind to the direct repeat 4 (DR-4) elements which
are similar to the response elements that LXRα binds to in the promoter regions
of target genes. Therefore, looking at LXRα target genes in this study may
determine if crosstalk between these three receptors is a significant interaction
altering steatosis.
The hepatic expression of fatty acid synthase (FAS), a classic LXRα target
gene was decreased with Aroclor 1260 exposure in WT mice (Fig. 3.11 A). In
contrast, FAS mRNA levels were up-regulated in the PXR knockout groups with
or without Aroclor 1260 exposure. Similar to FAS, the expression levels of
stearoyl coenzyme A desaturase1 (SCD1), another LXRα target gene, was
decreased with Aroclor 1260 exposure in the WT group (Fig. 3.11 B). However,
SCD1 expression was upregulated in the CAR knockout groups with or without
Aroclor 1260 exposure.
The hepatic expression of CD36, a fatty acid binding protein and a
common target gene of LXRα, PXR, AhR and PPARγ, was also assessed (Fig.
3.11 C). Interestingly, Aroclor 1260 exposure resulted in an increase in CD36
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expression in the WT group compared to the unexposed mice. The PXR-/- groups
showed relatively higher basal CD36 mRNA levels than any other group and
Aroclor 1260 exposure significantly induce CD36 in PXR-/- mice. The hepatic
expression of the fatty acid binding protein 1 (FABP1), another protein required
for fatty acid uptake and transport across the cell membrane was increased in
the CAR knockout groups and the exposed, PXR knockout group (Fig. 3.11 D).
Additionally, apart from the LXRα target genes that are involved in fat synthesis,
hepatic expression of the lipolytic gene, papatin like phospholipase domain
containing 2 (PNPLA2) was measured. Aroclor 1260 had no effect on PNPLA2
expression in WT mice (Fig. 3.11 E). However, Aroclor 1260 exposure induced
PNPLA2 in CAR-/- mice. In contrast, Aroclor 1260 exposure did not induce
PNPLA2 in PXR-/- mice but the basal levels of PNPLA2 expression were
elevated.
The sterol regulatory element binding protein (SREBP-1c) is a
transcription factor required for fatty acid biosynthesis and another transcriptional
regulator for lipogenic genes including FAS and SCD1. SREBP-1c cleavage to its
active form and subsequent translocation to the nucleus is controlled by many
factors. One of these factors is CAR and PXR inhibition of SREBP-1c cleavage
to its active form in the endoplasmic reticulum through the anti-lipogenic gene,
Insig (73). Insig binds to the SREBP cleavage activating protein (SCAB) and
prevents the cleavage of the SREBP precursor protein to its active form (112).
We hypothesized that CAR and PXR would induce Insig and subsequently inhibit
SREBP-1c cleavage to its active form (Fig. 3.12 A). Hepatic expression of
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SREBP-1c was analyzed and the PXR-/- mice exposed to Aroclor 1260 exhibited
higher SREBP-1c mRNA levels (Fig. 3.12 B). Hepatic expression of Insig-1 and 2
isoforms were therefore measured. Insig-1 mRNA levels were lower in the
Aroclor 1260 exposed mice in the WT and PXR knockout groups (Fig. 3.12 C).
Interestingly, CAR and PXR ablation also lowered Insig-1 hepatic expression. In
contrast, Insig-2 expression levels did not differ among the groups (Fig. 3.12 D).
To further investigate the underlying mechanisms that resulted in decreased
lipogenic gene expression (FAS, SCD1) in the exposed WT group but not in the
knockout groups, we measured the protein levels of SREBP1 in the mouse liver
(Fig. 3.12 E&F). Contrary to our hypothesis, CAR and PXR activation by Aroclor
1260 in the WT group did not result in lowered active SREBP1 isoform. Rather,
Aroclor 1260 exposure caused an increase in SREPB1 cleavage from the
inactive, precursor form that binds to the SREBP cleavage activating protein
(SCAB)-Insig complex.
However, as mentioned before, SREBP1 transcriptional activity is also
regulated by other factors such as the mammalian target of rapamycin complex 1
(mTORC1) (113). The total and phosphorylated mTOR1 protein levels in the liver
were quantified and the phosphorylated to total mTOR1 ratio which was
indicative of mTOR1 activation was calculated (Fig. 3.13 A). The knockout
groups demonstrated an increase in mTOR1 activation irrespective of Aroclor
1260 exposure. The phosphorylated to total AMP-activated protein kinase α
(AMPKα) protein levels were also quantified to assess AMPKα activation (Fig.
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3.13 B). Aroclor 1260 exposure activated AMPKα in the WT and PXR knockout
mice. The CAR knockout mice showed an increase in basal AMPKα active form.
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Figure 3.11. Effects of Aroclor 1260, CAR and PXR on hepatic expression of
lipogenic and lipolytic genes.
Real-time PCR experiments showed the changes in hepatic mRNA
expressions caused by Aroclor 1260 exposure alone and/ or by ablating CAR or
PXR for (A) FAS, (B) SCD1, (C) CD36, (D) FABP1 and (E) PNPLA2. Values are
mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260 exposure, # - ∆ due to knocking
out CAR or PXR.
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Figure 3.12. Effects of Aroclor 1260, CAR and PXR on hepatic SREBP-1c
expression and protein levels.
(A) Schematic diagram depicting CAR and PXR regulation on SREBP
through Insig. The diagram was adapted from Hellard et al., Molecular
Psychiatry, 14, 2009. Real-time PCR experiments showed the changes in
hepatic mRNA expressions caused by Aroclor 1260 exposure alone and/or by
ablating CAR or PXR for (B) SREBP-1c, (C) Insig-1 and (D) Insig-2. (E & F)
Immunoblots for precursor and cleaved SREBP1 were performed, n=5. Active
SREBP1 protein levels were quantified. Values are mean ± SEM, p <0.05, * - ∆
due to Aroclor 1260 exposure, # - ∆ due to knocking out CAR or PXR.
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Figure 3.13. Effects of Aroclor 1260, CAR and PXR on mTOR1 and AMPKα
protein levels.
(A) Immunoblots for mTOR1 and phosphorylated mTOR1 were performed.
The phosphorylated to total mTOR1 ratio was quantified. (B) Immunoblots for
AMPKα and phosphorylated AMPKα were performed. The phosphorylated to
total AMPKα ratio was quantified. Values are mean ± SEM, p <0.05, * - ∆ due to
Aroclor 1260 exposure, # - ∆ due to knocking out CAR or PXR.
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Effects of CAR/PXR on peroxisome proliferator-activated receptor alpha
target genes
Peroxisome proliferator-activated receptor alpha (PPARα) drives the
transcription of genes involved in breaking down fatty acids such as carnitine
palmitoyl transferase (CPTs) and Cyp4a10. Hepatic expression of PPARα as well
as its target genes, CPT1A and Cyp4a10 was measured. The PPARα mRNA
levels were higher in the Aroclor 1260-exposed mice compared to the unexposed
mice in the WT and PXR-/- groups (Fig. 3.14 A). Although unexposed CAR-/- mice
had increased PPARα mRNA levels vs. unexposed WT mice, Aroclor 1260 had
no effect on PPARα expression in CAR-/- mice. In contrast, CPT1A was induced
with Aroclor 1260 in all three groups irrespective of CAR/PXR ablation (Fig. 3.14
B). Additionally, the Aroclor 1260-exposed PXR-/- mice showed the highest
induction, and there was a significant interaction between PXR ablation and
Aroclor 1260 exposure which was consistent with PPARα induction. Furthermore,
Aroclor 1260 induced Cyp4a10 only in CAR-/- mice (Fig. 3.14 C). Also, PXR
ablation induced Cyp4a10 in the exposed mice.
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Figure 3.14. Effects of Aroclor 1260 exposure and CAR/PXR ablation on
hepatic PPARα expression and its target genes.
Real-time PCR experiments showed the changes in hepatic mRNA
expressions caused by Aroclor 1260 exposure alone or by ablating CAR or PXR
as well for (A) PPARα, (B) CPT1A and (C) Cyp4a10. Values are mean ± SEM, p
<0.05, * - ∆ due to Aroclor 1260 exposure, # - ∆ due to knocking out CAR or
PXR.
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CAR and PXR target gene induction
CAR hepatic mRNA levels were measured and as anticipated, there was
no CAR mRNA in the CAR-/- mice. Aroclor 1260 exposure increased CAR mRNA
expression (~2-fold) in WT mice (Fig. 3.15 A). PXR ablation also increased CAR
mRNA expression by ~10-fold as compared to WT groups. There was also a
significant interaction between PXR ablation and Aroclor 1260 exposure in CAR
induction. The mRNA levels of Cyp2b10, a CAR target gene, were significantly
up-regulated in Aroclor 1260-exposed mice in the WT and PXR-/- groups (Fig.
3.15 B). Moreover, the basal mRNA levels of Cyp2b10 were higher in the
knockout groups, indicating a compensatory mechanism was driving CAR target
gene expression in the absence of CAR. Notably, Aroclor 1260 did not induce
Cyp2b10 in the CAR-/- group.
Hepatic expression of PXR was also evaluated, and as expected, there
was no PXR mRNA in the PXR-/- mice (Fig. 3.15 C). Aroclor 1260 did not induce
PXR mRNA expression in the WT mice. In contrast Aroclor 1260 exposure did
increase PXR expression (~17-fold) in the CAR-/- mice. Hepatic Cyp3a11 (PXR
target gene) mRNA levels were up-regulated with Aroclor 1260 exposure in the
CAR-/- group but not in the WT group (Fig. 3.15 D). Akin to Cyp2b10 expression,
the Cyp3a11 basal expression levels were higher in the knockout groups.
However, Aroclor 1260 did not induce Cyp3a1 in the PXR-/- group. Besides
Cyp3a11, the hepatic expression of Ugt1a1, a predominant PXR target gene
which also happens to be a CAR target gene, was measured (Fig. 3.15 E).
Aroclor 1260 induced Ugt1a1 in the WT and CAR-/- groups. Interestingly, Ugt1a1
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basal expression levels were higher only in the in the PXR-/- group but not in the
CAR-/- group.
Apart from CAR and PXR targets, the hepatic expression of Cyp1a2, an
aryl hydrocarbon receptor (AhR) target gene was also measured (Fig. 3.15 F).
There were no significant differences in the Cyp1a2 mRNA levels between the
groups indicating that the AhR was not activated by Aroclor 1260 at the dose
used and there was no effect of CAR or PXR ablation on AhR target gene
expression.
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Figure 3.15. Aroclor 1260 exposure altered hepatic expression of CAR and
PXR target genes.
Real-time PCR experiments showed the changes in hepatic mRNA
expressions for (A), CAR, (B) Cyp2b10 (CAR target gene), (C) PXR, (D)
Cyp3a11 (PXR target gene), (E) Ugt1a1 (PXR/CAR target gene)and (F) Cyp1a2
(AhR target gene). Values are mean ± SEM, p <0.05, * - ∆ due to Aroclor 1260
exposure, # - ∆ due to knocking out CAR or PXR.
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DISCUSSION
Aroclor 1260 was one of the first PCB mixtures manufactured and was
later replaced by PCB mixtures with lower chlorine content. Although constituting
only 11% of PCB mixtures manufactured, Aroclor 1260 was selected for this
study based on its similarity to human PCB bioaccumulation patterns. The PCB
congener composition in Aroclor 1260 consists of high molecular weight PCBs
such as 5-, 6-, and 7-chlorinated congeners that are either not or very poorly
metabolized so these congeners bio-accumulate in human and other biota. Most
PCB studies in the past literature focused on occupational acute exposures that
were associated with cancer-related endpoints and AhR activation. More
recently, epidemiologic studies have revealed that PCB-exposed human cohorts
showed signs of cardiovascular disorders, obesity, diabetes/insulin resistance
and elevated liver enzymes (46, 52, 114).
Clearly, chronic exposures to PCBs appear to disrupt lipid and glucose
homeostasis and consequently lead to increased symptoms of diabetes and the
metabolic syndrome in the exposed subjects (34, 52). Mechanistically, PCB
action is thought to be mediated by the AhR and CAR. However, PCBs have also
been shown to interact with endocrine and thyroid receptors as well as additional
hepatic nuclear receptors including the PXR (97-99). Albeit being xenobiotic
receptors, CAR and PXR are also involved in energy metabolism by acting
directly or indirectly on enzymes involved in lipid and glucose metabolism (6062). We previously demonstrated that Aroclor 1260 induced liver injury in
conjunction with HFD feeding. We also demonstrated that Aroclor 1260 activated
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CAR and PXR in C57Bl/6 mice at 20 mg/kg exposure. The current study aimed
at examining the role of CAR and PXR in Aroclor 1260-induced liver injury by
using diet-induced obese CAR and PXR knockout mice.
The findings from the study demonstrated that PXR was important in
maintaining lower fat mass and liver weight because ablating this receptor
resulted in increased adiposity/liver weight (Fig. 3.1). CAR ablation did not
appear to interfere with adiposity. In fact, Aroclor 1260 exposure decreased
bodyweight gain in CAR knockout mice, which may be due to increased physical
activity and less food consumption displayed by this group. Interestingly, PXR
was also over-expressed in this group. Presence of CAR and PXR also appeared
crucial in maintaining energy homeostasis because ablating these receptors
decreased the RER relative to WT mice, indicating only a lipid-metabolism state
(Fig. 3.3). However, activation of either receptor by Aroclor 1260 restored the
RER to a level similar to WT groups.
When inflammation was examined, CAR and PXR ablation did not
improve steatohepatitis induced by Aroclor 1260. Both CAR and PXR knockout
mice showed signs of hepatic inflammation on high fat diet feeding alone, as
evident by the TNFα and IL-6 basal expression levels (Fig. 3.6). These results
suggested that both CAR and PXR play an inhibitory role in inflammation and
activating these receptors by Aroclor 1260 is a protective mechanism in
attenuating Aroclor 1260-induced toxicity. The role of PXR in inflammation is well
documented relative to CAR (115). It is well known that exposure to xenobiotic
chemicals such as rifampicin compromises the immune function and recent
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studies have investigated the molecular mechanisms involved between PXR
activation and inflammation. Zhou et al demonstrated that the interaction
between PXR and nuclear factor kappa B (NF-κB) appeared to be reciprocal with
both transcription factors mutually inhibiting each other (116). Enhanced
expression of NF-κB target genes including TNFα, IL-2 and IL-6 was observed in
the small bowel and liver of PXR knockout mice which was consistent with
observations in the current study. Hu et al also showed increased hepatic
expression of inflammatory cytokines in PXR knockout mice and demonstrated
that liganded PXR was SUMOylated in hepatocytes in response to TNFα (117).
Intriguingly; the SUMOylated PXR protein suppressed NF-κB target gene
expression but had no effect on PXR target gene expression such as CYP3A4.
The relationship between CAR and the inflammatory process is poorly
understood, although some observations have implied its basal repression
activity on NF-κB signaling (115). In the present study, it should be noted that
even though Aroclor 1260 activated CAR/PXR in WT mice, their activation was
not sufficient to protect the mice from hepatic and systemic inflammation,
implying that Aroclor 1260 may affect liver injury by mechanisms other than the
classically-defined receptor mechanisms.
Cell culture studies indicated that activators of CAR and PXR repress
hepatic gluconeogenic enzymes and therefore, CAR/PXR modulation of glucose
metabolism possibly resulted in lowered blood glucose levels (71, 75). CAR and
PXR inhibit gluconeogenic gene transcription, including PEPCK-1 and G6Pase,
by directly binding to the transcription factor, forkhead boxO1 (FOXO1) and
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preventing its transcriptional activity (74). CAR can also interfere with
gluconeogenic gene expression by competing with the hepatocyte nuclear factor
4 alpha (HNF4α) for binding at the PEPCK-1 promoter region. Also, CAR and
PXR target the common co-activator utilized by numerous transcription factors,
peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α),
resulting in the ‘squelching’ of PGC1α (118, 119).
In the current study, hepatic expression of PEPCK-1 was enhanced in
both CAR and PXR knockout mice (Fig. 3.9), implicating the loss of CAR- and
PXR-inhibitory effect on PEPCK-1 transcription. PEPCK-1 was also induced with
Aroclor 1260 exposure in the knockout mice, noticeably in PXR-/- mice,
suggesting that PCB exposure increased gluconeogenic gene expression in
absence of either CAR or PXR. Although fasting blood glucose levels were
unchanged, all Aroclor 1260-exposed groups showed decreased serum insulin
and HOMA-IR levels (Fig. 3.8). This observation is consistent with findings from
our previous studies, associating compromised insulin secretion with PCB
exposure, independent of CAR and/or PXR presence and activation. Thus the
PXR knockout mice exposed to Aroclor 1260 showed increased AUC in a
glucose tolerance test, potentially due to increased gluconeogenesis and
decreased insulin synthesis required for glucose uptake.
Another compelling observation in this study was the decreased
leptin:adiponectin ratio in CAR and PXR knockout mice (Fig. 3.10). Circulating
leptin:adiponectin ratio is considered a potential surrogate biomarker for obesityrelated conditions with higher leptin levels being observed consistently with
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metabolic syndrome and diabetes/insulin resistance (120). In this study, serum
adiponectin levels were higher in the knockout mice whereas leptin levels were
not altered between the groups. Nonetheless, PXR knockout mice did not show
any improvement in diet-induced obesity, despite the favorable leptin:adiponectin
ratio while the CAR knockout mice displayed reduced adipocyte size.
Aroclor 1260 exposure resulted in decreased FAS expression in WT mice
(Fig. 3.11). However, the PXR knockout mice showed increased FAS basal
levels indicating that activated PXR repress FAS transcription. Likewise, SCD1
expression was decreased with Aroclor 1260 exposure; however its basal levels
were increased only in CAR knockout mice suggesting that CAR could be a
transcriptional repressor of SCD1. This supports other studies documenting
decreased hepatic expression of lipogenic genes such as FAS and SCD1 during
CAR activation (71, 72). Moreover, CAR suppression of LXRα transcriptional
activity has also been reported, which could then cause downregulation of
lipogenic gene expression (121). Additionally, Aroclor 1260 did not induce FAS or
SCD1 in CAR knockout mice, therefore, this PCB mixture may not be a direct
LXRα activator. In contrast, SREBP-1c was significantly induced only in PXR
knockout mice exposed to Aroclor 1260, suggesting an interaction between PCB
exposure and PXR ablation. However, simply measuring SREBP-1c expression
alone may not be sufficient to determine the CAR/PXR effects on lipogenesis
since both CAR and PXR also affect SREBP-1c activity through the anti-lipogenic
gene, Insig (73). Therefore, it was more appropriate to measure active SREBP1c levels in the liver.
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Contrary to our hypothesis, there was no reduction in active SREBP1
protein levels with Aroclor 1260 exposure (Fig. 3.12). Rather, the Aroclor 1260
exposed groups in the WT and CAR knockout mice had higher cleaved SREBP1
protein levels than the unexposed group. Additionally, since the exposed groups
did not show an increase in hepatic Insig-2 expression either, it appeared that
CAR/PXR activation and ablation did not modulate hepatic gene expression
through the Insig2-SCAB-SREBP1 pathway. Notably, hepatic Insig-1 expression
was decreased in the Aroclor 1260 exposed groups. Insig-1 regulates the SCABSREBP2 complex and its expression is regulated in part by nuclear SREBP
levels and sterol deprivation (122). Furthermore, although it has been reported
that CAR and PXR regulate lipogenesis by inducing Insig-1, the SREBP1
retention in the endoplasmic reticulum has also been reported to be via Insig-2
binding (123). However, Insig-2 expression did not differ among the groups.
CAR and PXR ablation appeared to activate the mTOR1 complex pathway
and Aroclor 1260 exposure appeared to activate AMPKα (Fig. 3.13). These are
intriguing observations because mTOR and AMPK are considered as ‘energy
sensors’ that regulate carbohydrate and lipid metabolism, thereby maintaining
energy homeostasis at the cell and whole body level (124, 125). mTOR activation
occurs during high nutrient availability or ‘fed’ state and usually favors anabolic,
ATP-consuming processes that facilitate storage of nutrients such as lipogenesis
and protein synthesis. Regulation of lipogenic SREBP1 by mTOR1 occurs at
multiple levels (126). It has been demonstrated that high insulin levels can
activate the mTOR1 complex through the Akt phosphorylation pathway (127).
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Phosphorylated mTOR can phosphorylate the phosphatidic acid phosphatase
Lipin-1, a transcriptional coactivator (113). Nuclear localized, dephosphorylated
Lipin-1 inhibits SREBP1 nuclear localization and subsequently SREBP1
transcriptional activity. Hence mTOR1 activation eventually leads to increased
SREBP1 nuclear localization and activity. In this study, mTOR1 activation in the
knockout groups possibly resulted in observable inductions of lipogenic gene
expression. Interestingly, the WT mice exposed to Aroclor 1260 showed lower
FAS and SCD1 expression which corroborated with lower phosphorylated
mTOR1 levels. Moreover, the Aroclor 1260-exposed mice had lower insulin
levels and this may have led to decreased phosphorylated mTOR1 levels
compared to the unexposed mice in the WT group. However, this effect was lost
with CAR and PXR ablation and the mechanisms related to this observation need
to be investigated further.
In contrast to mTOR1, AMPKα activation occurs during low nutrient
availability or ‘fasted’ state and favors catabolic processes such as glycolysis
(128). Besides, downstream AMPK signaling also inhibits anabolic processes
that consume ATP. The mechanism involving AMPKα activation by Aroclor 1260
exposure in the current study is unclear. However, AMPKα activation could be
the reason for the increase in RER in the Aroclor 1260 exposed, PXR knockout
mice. The same explanation could not be applied to the CAR knockout group
because CAR ablation appeared to activate AMPKα irrespective of Aroclor 1260
exposure. Also, it has been reported that metformin, an AMPK activator, inhibits
CAR nuclear translocation and activation, indicating a complex relationship
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between CAR and AMPK (129). Therefore more studies are necessitated with
regard to PCB exposure and the mTOR and AMPK activation pathway.
Aroclor 1260 induced CD36, a shared target gene of PXR, AhR and LXRα
in WT mice (Fig. 3.11). It is known that PXR activators such as rifampicin can
promote steatosis independent of the SREBP1 pathway by up-regulating hepatic
CD36 (130). Interestingly, ablating PXR increased CD36 basal expression,
implying that there may be some compensatory mechanisms affecting CD36
expression in the absence of PXR. Furthermore, CD36 was also induced in the
absence of PXR, indicating that Aroclor 1260 had other targets related to CD36
induction and not restricted to PXR activation. Apart from lipogenic genes, the
lipolytic gene PNPLA2 (adipose triglyceride lipase) was also evaluated. PNPLA2
is expressed primarily in the adipose tissue as well as in the liver (131); it is
involved in breaking down triglycerides to free fatty acids and one of its
transcriptional mediators is FOXO1 which is in turn controlled by many factors
including sirtuins (SIRT1) and insulin (132, 133). Being a FOX01 target gene, we
assumed that hepatic PNPLA2 expression pattern in our study would be similar
to that of PEPCK-1. Aroclor 1260 induced PNPLA2 in CAR knockout mice,
similar to PEPCK-1. However in PXR knockout mice, the basal levels of hepatic
PNPLA2 were increased and Aroclor 1260 induction was not observed,
suggesting that PXR rather than CAR may be dominant in the sequestration of
FOXO1 under basal conditions. Moreover, PEPCK-1 basal levels were also
higher in PXR knockout mice when compared to CAR knockout mice.
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Another distinct finding in this study was the regulation of PPARα target
genes by CAR/PXR and Aroclor 1260 exposure (Fig. 3.14). Aroclor 1260 by itself
increased PPARα expression in WT and PXR knockout mice but not in CAR
knockout mice, suggesting that Aroclor 1260 exposure induced PPARα but
activated PXR negatively regulates this induction. Interestingly, Aroclor 1260
induced CPT1A, a PPARα target gene and rate limiting enzyme of mitochondrial
fatty acid β-oxidation, in all three groups, and this was highest in the PXR
knockout mice. Studies have shown the repression of CPT1A and other βoxidation related genes with PXR and CAR activation and their enhanced
expression in knockout models (72, 77, 134). Apart from PPARα, CPT1A
transcription is also mediated by the forkhead box protein A2 (FOXA2 ) and
HNF4α (135, 136). PXR is a known inhibitor of FOXA2, and hence its ablation
increased FOXA2 basal expression and inducibility by Aroclor 1260 (105).
FOXA2 activity is also positively regulated by low levels of insulin which was
displayed by all the Aroclor 1260-exposed groups (137). Another plausible
mechanism for increased CPT1A expression in the knockout mice could be the
increased availability of the peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PCG1α) for HNF4α transcriptional activity. Cyp4a10, another
PPARα target and enzyme involved in peroxisomal fatty acid oxidation, was
induced with Aroclor 1260 exposure in CAR knockout mice. This finding is
consistent with studies by Ueda et al, demonstrating that CAR is a negative
regulator of Cyp4a10 expression and hence knocking out CAR enhanced
Cyp4a10 induction by Aroclor 1260 (134).
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Overall, our studies strongly indicated that CAR and PXR played a role in
energy metabolism and validated previous findings that demonstrated xenobiotic
receptor activation acts as an important factor in fatty liver disease and the
metabolic syndrome (Fig. 3.16). In the current model, CAR and PXR activation
appear to protect rather than augment Aroclor 1260-induced liver injury evident
with worsened inflammation in CAR and PXR knockout mice. Moreover, the
concept that CAR is an anti-obesity receptor and PXR is an obesity-promoting
receptor may not reflect the complexity of Aroclor 1260 or environmental
contaminant interaction with these transcription factors. It appears that both
receptors are required for normal physiology and function and that they both
portray similar if not identical outcomes on activation. Furthermore, our studies
are consistent with previous observations on the effects of CAR and PXR in
glucose and lipid metabolism. In contrast to the previous studies that employed
model CAR and PXR ligands, this study used an environmental pollutant with
multiple potential targets, which may also influence the end results of the study.
These studies used knock out models to evaluate the distinct effects of these
nuclear receptors in energy metabolism but it appears that Aroclor 1260
exposure also causes other effects such as compromised insulin levels. In
conclusion, nuclear receptors CAR and PXR are not merely detoxification
receptors but they also have an important role in inflammation and endobiotic
metabolism as well; both CAR and PXR play an important protective role in liver
injury caused by environmental pollutant, Aroclor 1260.
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Figure 3. 16. Effects of CAR and PXR on hepatic energy metabolism.
A schematic diagram depicting the potential therapeutic role of CAR and PXR
activation in the metabolic syndrome. Figure adapted from Gao, et al., Trends
Pharmacol Sci, 33 (10), 2012.
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CHAPTER 4
HUMAN RECEPTOR ACTIVATION BY AROCLOR 1260 AND INDIVIDUAL
PCB CONGENERS
INTRODUCTION
NAFLD and NASH were traditionally associated with the inappropriate
over- or under-activation of nuclear receptors involved in endobiotic metabolism.
These receptors include the LXR, farnesoid-X-receptor (FXR) and PPARs which
regulate cholesterol, bile acid and lipid metabolism respectively (58, 59). Recent
studies have implicated the role of hepatic receptors involved in xenobiotic
detoxification, including PXR, CAR and the AhR in NAFLD/NASH. Although
these receptors were initially thought to be involved only with detoxification and
xenobiotic metabolism, over-activation or antagonism of these receptors may
lead to metabolic disease states such as steatosis and obesity (60-62).
Historically, PCB toxicity has been linked to cancer, endocrine disruption
and impaired cognitive development, but recent studies have shown that chronic
exposure to these environmental pollutants can result in metabolic disorders
associated with NAFLD, including obesity, insulin resistance/diabetes and the
metabolic syndrome (41, 102). Additionally, rodent studies have correlated PCB
exposures with NAFLD, obesity and the metabolic syndrome suggesting the
involvement of distinct nuclear receptors in PCB-mediated toxicity (48). It
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remains unclear if the liver disease caused by PCB exposure is due to the direct
involvement of receptors that regulate endobiotic metabolism such as LXR and
FXR or if the disease process is linked to the activation/inhibition of xenobiotic
receptors such as PXR and CAR.
We hypothesized that PCBs may exert some of their toxic effects, such as
NAFLD, by either interacting directly with the endobiotic nuclear receptors (LXR,
FXR, PPARs) or through interaction with xenobiotic receptors that cross-talk with
endobiotic receptors to otherwise modify their respective interactions with DNA
response elements. Moreover, the interaction between Aroclor 1260 and these
receptors that are implicated in NAFLD have never been tested. The purpose of
this study is to evaluate the receptor agonism/antagonism by the PCB mixture,
Aroclor 1260, and selected PCB congeners that are highly represented in this
mixture. For the purpose of the studies, we collaborated with Dr. CJ Omiecinski
from Penn State University to study PCB activation of the human CAR variants
using COS-1 cells.
The study demonstrated selective activation by Aroclor 1260 and selected
PCB congeners on human AhR, PXR and CAR, and inhibition of PPARα. We
postulate that hepatic transcription factor activation is part of the mode of action
of these organo-chlorine pollutants.
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MATERIALS AND METHODS
Materials
Aroclor 1260 was purchased from AccuStandard (New Haven, CN, USA)
and PCB congeners were obtained from Ultra Scientific (North Kingstown, RI,
USA). T0901317 (N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide), GW3965 (2-(3-(3-((2-chloro3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl) acetic acid
hydrochloride), GW4064 (3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl] benzoic acid) and pioglitazone
were obtained from Tocris Bioscience (Bristol, UK). Dimethyl sulfoxide (DMSO)
was acquired from Fisher BioReagents (Thermo Fisher Scientific, Pittsburg, PA,
USA) while 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4dichlorobenzyl)oxime (CITCO), rifampicin (RIF), benz[a]anthracene (BA) and 3(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) were from
Sigma Aldrich (St. Louis, MO, USA). Restriction endonucleases and T4 DNA
ligase were purchased from New England BioLabs (Ipswich, MA). Lipofectamine
and Opti-MEM were obtained from Life Technologies Inc (Carlsbad, CA, USA).
Oligonucleotides were purchased from Integrated DNA Technologies (Coralville,
IA, USA).
Plasmid construction
The reporter plasmids for human (h) PXR (pGL3-DR4-Luc), hFXR (pGL3IR1-Luc) and hPPARα (pGL3-DR1-Luc) were constructed by using two copies of
a direct repeat 4 (DR4), an inverted repeat 1 (IR1) and a direct repeat 1(DR1)
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response element (RE) respectively. The top strand oligonucleotide was 5’
AGAGTTCATGAGAGTTCATGAGAGTTCATGAGAGTTCATG 3’ for pGL3-DR4Luc, 5’ AGAGGTCATTGACCTTTAGAGGTCATTGACCTTT 3’ for pGL3-IR1-Luc
and 5’ AACTAGGTCAAAGGTCAAACTAGGTCAAAGGTCAAA 3’ for pGL3-DR1Luc. Both the bottom complementary strands had Kpn1 and Xho1 overhangs at
the 5’ and 3’ positions respectively. The oligonucleotides were annealed and
inserted into Xho1 and Kpn1 restriction sites in the polycloning region of a
modified version of pGL3 promoter vector (Promega, Madison, WI, USA).
Reporter plasmid for AhR (pXRE-SV40-Luc) was synthesized using the
oligonucleotide 5’ TCAGGCATGTTGCGTGCATCCCTGAGGCCAGCC 3’
inserted into the EcoR1 site of a modified version of pGL3 promoter vector.
Expression vectors pSG5-hLXRα, pSG5-hPXR and pSG5-hFXR and reporter
plasmid pTK-LXRE-Luc were a generous gift from John Y. Chiang (Department
of Integrative Medical Sciences, Northeast Ohio Medical University). Expression
vectors pCMV6-hPPARα, pCMV6-hPPARγ and pCMV6-hCAR (CAR2) were
purchased from Origene (Rockville, MD, USA). The vectors, pTracer CMV2hCAR1, pTracer CMV2-hCAR2, pcDNA 3.1-RXRα, and pGL3- basic/TK
CYP2B6-dervied XREM/PBREM were described previously (138). pTracer
CMV2-CAR3 was also reported previously (139). pRL-CMV, the expression
plasmid encoding Renilla luciferase, was purchased from Promega (Madison,
WI, USA) and used in the Dual-Glo (Promega) assay system according to the
manufacturer’s protocol to normalize for transfection efficiencies in cultured cells.
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Prior to transfection, plasmids were prepared using the Qiagen Plasmid Plus Midi
Kit (Qiagen, Valencia, CA, USA).
Cell culture
HepG2 cells: The human hepatoma-derived cell line (HepG2) was
obtained from the American Type Culture Collection (ATCC, Manassas, MD,
USA). Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM,
HyClone Laboratories Inc, Thermofisher, Waltham, MA, USA) supplemented with
10% fetal bovine serum (FBS) and 1% antimycotic/antibiotic solution (Mediatech,
Manassas, VA, USA). The cells were incubated in a 5% carbon dioxide
atmosphere and 95% humidity at 37 °C and subcultured every 2 days.
COS-1 cells: COS-1 cells (Simian virus-40–transformed African green
monkey kidney cells) were obtained from the ATCC and maintained in DMEM
plus GlutaMAX-I with 10% FBS,10mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), 1mM sodium pyruvate, 13 non-essential
amino acids, and 1% penicillin/streptomycin. COS-1 cells were cultured at 37 °C
in a humidified atmosphere containing 5% carbon dioxide. All cell culture
reagents were purchased from Life Technologies (Grand Island, NY, USA).
Cell viability assay
HepG2 cells were seeded in 96-well tissue culture plates at a seeding
density of 10,000 cells per well. Cells were treated with graded concentrations of
Aroclor 1260 made up as 500X stocks in DMSO. Controls received DMSO only.
After 24 h incubation, MTT (0.2 mg/ml) was added to the cells and incubated for
3-4 h. The media were removed from the plates by aspiration and formazan dye
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was liberated by adding 50 µL DMSO. MTT, a yellow tetrazole, was reduced to
an insoluble product formazan by mitochondrial reductases, indicative of cell
viability. Presence of formazan, a purple precipitate, was determined
spectrophotometrically at 540 nm using a Bio-Tek Synergy HT multi-mode micro
plate reader (Winooski, VT, USA).
Transfection
HepG2 cells were plated in Thermo Scientific Nunc 24-well plates and
transfected at 40-60% confluence. Unless otherwise specified, the transfection
mix per well contained 150 ng β-galactosidase expression plasmid (pCMV-β,
Stratagene, CA) as a transfection control, 50 ng receptor expression plasmid and
150 ng reporter plasmid. All cells were co-transfected by lipofection using
Lipofectamine reagent according to the manufacturer’s instructions and OptiMEM (reduced serum medium) as the transfecting medium. After 4 hour
incubation, the medium was changed to DMEM supplemented with 10% FBS
and 1% antimycotic/antibiotic solution and cells were allowed to recover
overnight. DMEM supplemented with charcoal/dextran treated FBS (HyClone
Laboratories Inc, Thermofisher, Waltham, MA, USA) was used for PPAR
activation assays. Compounds of interest were then added to the cells (n=4) and
cells were incubated for 24 h. DMSO was used as a carrier for all compounds
(final concentration <0.5%). For COS-1 cells, all media components remained the
same except that FBS was replaced with 10% dextran/charcoal-treated FBS
(HyClone, Logan, UT, USA). The details of the luciferase reporter assays were
described previously (138-140). Briefly, approximately 1 h prior to transfection,
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cells were trypsinized and plated onto 48-well plates (~50,000 cells per well). For
determination of transcriptional activity of the hCAR constructs, cells were
transfected using Fugene 6 (Promega) according to the manufacturer’s
recommendations with a co-transfection plasmid mix consisting of 10 ng pRLCMV (Renilla luciferase) for normalization, 25 ng pcDNA 3.1-RXRα, 100 ng of
pGL3-basic/TK XREM/PBREM luciferase reporter plasmid, and 25 ng of pTracer
vectors containing the various CMV2-CAR expression constructs. Each condition
was performed in quadruplicate. Aroclor 1260 and each of the PCBs were
evaluated at 10 µM. DMSO was used as a solvent control. CITCO, 5 µM, was
used as a positive control. Androstanol (ANDR), a known inverse agonist of
human CAR, was used as a control for CAR1.
Reporter assay
HepG2 cells: Cells were washed twice with Phosphate Buffered Saline
(1X), harvested using 50 µL cell lysis buffer (Promega, Madison, WI, USA) and
subjected to a single freeze-thaw event. For β-galactosidase assays, cell
extracts (5 µL), were incubated with chlorophenol red β-galactopyranoside
(CPRG, Roche Diagnostics, Indianapolis, IN) at 37 °C for 30-60 minutes. The
enzyme activity was determined spectrophotometrically at 595 nm using the BioTek Synergy HT multi-mode micro plate reader. Luciferase activity assays were
performed on cell extracts (5 µL) using the Luciferase Assay System (Promega).
Luminescence was measured using the Orion L micro plate luminometer
(Berthold Detection Systems, Pforzheim, Germany) over a 10 second period.
Receptor activation was measured by luciferase activity and results were
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normalized to the amount of β-galactosidase expressed. COS-1 cells: Luciferase
assays were performed using the Dual-Glo Reporter Assay System (Promega)
and a Veritas Microplate Luminometer (Turner Biosystems, Sunnyvale, CA,
USA). Firefly (Photinus pyralis) luminescence data values were recorded for
each replicate and normalized luciferase activities were then calculated by
dividing the raw luciferase values by the Renilla luciferase signals to correct for
any differences in transfection efficiency among the assay wells.
Validation of receptor activation in primary human hepatocytes
Human hepatocytes were obtained from BioreclamationIVT (Baltimore,
MD, USA). Hepatocytes were thawed and plated in 12-well plates according to
the supplier’s protocols and the compounds of interest were added. The cells
were incubated for 24 h and RNA was extracted using RNA STAT-60 protocol
(Tel-test, Austin, TX, USA). RNA purity and quantity were assessed with the
Nanodrop (ND-1000, Thermo Scientific, Wilmington, DE, USA) using the ND1000 V3.8.1 software. cDNA was synthesized from total RNA using the
QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA). Polymerase
chain reaction (PCR) was performed on the Applied Biosystems StepOne Plus
Real-Time PCR Systems using the Taqman Universal PCR Master Mix (Life
Technologies, Carlsbad, CA, USA). Each PCR mix (20 µL) contained: Taqman
Universal PCR Master Mix (10 µL), 20X Gene Expression Assay Mix (1 µL),
cDNA sample (2 µL) and nuclease-free water (7 µL). Primer sequences from
Taqman Gene Expression Assays (Applied Biosystems, Foster City, CA, USA)
were as follows: cytochrome P450s [CYP3A4 (Hs00604506_m1), CYP2B6
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(Hs04183483_g1), CYP1A1 (Hs01054797_g1)], CD36 (Hs01567185_m1), fatty
acid synthase (FAS) (Hs01005622_m1), carnitine palmitoyl transferase 1A
(CPT1A), (Hs00912671_m1), small heterodimeric partner (SHP)
(Hs00222677_m1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Cycle conditions were maintained according to the Applied Biosystems guide.
The levels of mRNA were normalized relative to the amount of GAPDH mRNA,
and expression levels in DMSO-exposed cells were set at 1%. Gene expression
levels were calculated according to the 2-∆∆Ct method (92).
Statistical analysis
Statistical analyses were performed using GraphPad Prism version 5.01
(San Diego, CA, USA). In general for all assays, data are expressed as means ±
SEM. Quantitative data for two group comparisons were assessed using an
unpaired t-test. Multiple group data were examined by one way analysis of
variance followed by the Dunnett’s post hoc test to compare all groups to the
control sample. Multiplicity adjusted p values are reported in the Results section.
P <0.05 was considered statistically significant.
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RESULTS
Cell viability assay for Aroclor 1260
MTT assays were performed to determine the optimal concentration for
Aroclor 1260 that does not cause toxicity in HepG2 cell culture experiments.
Cells were exposed to this PCB mixture at concentrations ranging from 1.25 250 µg/mL. The optical density for formazan, representative of cell viability, was
plotted against Aroclor 1260 concentrations. The toxicity threshold (concentration
that caused 50% cell death) was determined to be 26.0 ± 3.7 µg/mL (Fig. 4.1).
Concentrations of Aroclor 1260 at 5, 10, 15 and 20 µg/mL were selected for
subsequent experiments.
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Figure 4.1. Cell viability assay for Aroclor 1260.
HepG2 cells were exposed to Aroclor 1260 at concentrations ranging from
1.25 - 250 µg/mL and the optical density for formazan was measured.
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Aroclor 1260 activation of the human aryl hydrocarbon receptor
Coplanar PCBs (PCBs 126 and 77) activate AhR in rodents and hence
are classified as “dioxin-like” PCBs. Coplanar congeners comprise only ~1% of
the total composition in Aroclor 1260. HepG2 cells, co-transfected with pXRESV40-Luc, were exposed to various concentrations of Aroclor 1260 for 24 h and
the normalized luciferase activity was measured. As anticipated, AhR was
activated by its polycyclic aromatic hydrocarbon ligand BA (10 µM), and Aroclor
1260 exposure resulted in a significant increase in luciferase activity (3.5-fold at
20 µg/mL, p <0.0001) compared to DMSO-exposed cells (Fig. 4.2 A). However,
this fold induction was relatively low when compared to that of BA. These results
indicate that Aroclor 1260 has a weak AhR agonistic activity that is likely due to
the presence of coplanar congeners at lower concentrations in the mixture. AhR
activation by BA was assessed in the presence of increasing concentrations of
Aroclor 1260 to evaluate for any potentiation or antagonism effects. Cells coexposed to BA and Aroclor 1260 showed no difference vs. BA-exposed cells only
(Fig. 4.2 B).
Next, we selected ten non-coplanar congeners that are more highly
represented in Aroclor 1260 mixture (≥1%) as well as two coplanar congeners
(PCBs 126 and 118) and tested the ability of these compounds to individually
activate AhR at a concentration of 10 µM. Although PCB 126 (no ortho)
constitutes ~0.002% of the total PCB composition in Aroclor 1260, it was
selected for this study because it is a good AhR activator (141). PCB 118 (monoortho) was chosen because it was one of the coplanar congeners with the
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highest composition in Aroclor 1260 (0.48%). Among the selected congeners,
coplanar PCB 126 and non-coplanar PCB 138 significantly induced luciferase
activity (17-fold, p <0.0001 and 4-fold, p =0.0006 respectively), while coplanar
PCB 118 did not induce luciferase activity (1.2-fold) compared to DMSO-exposed
cells (Fig. 4.2 C). Thus it appeared that PCB 118 did not activate AhR at the
concentration used, unlike PCB 126. Besides, AhR activation was not restricted
to only coplanar congeners because PCB 138 modestly activated AhR.
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Figure 4.2. Aroclor 1260 activation of the human AhR.
HepG2 cells were transiently transfected with the reporter plasmid pXRESV40-Luc. Benz[a]anthracene (10 µM, BA) was used as a positive control. (A)
Cells were exposed to Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL and luciferase
induction was normalized and compared to DMSO-exposed cells (0 µg/mL
Aroclor 1260). (B) Cells were exposed to 10 µM BA or BA plus Aroclor 1260 at 0,
5, 10, 15 and 20 µg/mL. The luciferase induction was normalized to that of cells
exposed only to DMSO solvent carrier (as in A, not shown). Luciferase activity in
cells exposed to BA and Aroclor 1260 was compared to that of BA-exposed cells.
(C) Cells were exposed to selected PCB congeners (10 µM) present in Aroclor
1260 and the induction was compared to DMSO-exposed cells. Data were
normalized to luciferase activity in cells exposed only to DMSO and are
expressed as mean ± SEM, n=4, * p <0.05. Figure adapted from Wahlang et al.,
Toxicol Sci, 140 (2), 2014.
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Aroclor 1260 activation of the human pregnane xenobiotic receptor
Non-coplanar PCBs, including PCBs 153 and 196, have been predicted to
activate the nuclear receptors PXR and CAR, and these PCBs are often referred
to as “phenobarbital-like”. Apart from regulating xenobiotic metabolism, PXR
activation is implicated in weight gain and obesity (60, 142). Moreover, since
PXR and CAR do share similar ligands to an extent, it is therefore likely that
Aroclor 1260, being largely composed of non-coplanar PCBs, will activate PXR.
HepG2 cells, co-transfected with pSG5-hPXR and pGL3-DR4-Luc were
exposed to various concentrations of Aroclor 1260 for 24 h. RIF (10 µM), a PXR
ligand, was used as a positive control. RIF activated PXR-driven luciferase
activity (2.6-fold, p <0.0001) whereas Aroclor 1260 activated the receptor in a
concentration-dependent manner with a Km value of 8.75 µg/mL (Fig. 4.3 A).
Cells exposed to Aroclor 1260 at 5 µg/mL showed no significant induction in
luciferase activity as compared to cells exposed to DMSO only. However, the
induction was significant at concentrations of 10 (1.9-fold, p =0.0024), 15 (2.1fold, p =0.0001) and 20 (2.7-fold, p <0.0001) µg/mL. When transfected cells were
exposed to both RIF and Aroclor 1260 (5 µg/mL and above) simultaneously,
there was a slightly higher induction (~18%) compared to RIF-exposed cells
alone (Fig. 4.3 B) but this was not significant. These data suggest that Aroclor
1260 activated the PXR reporter system at concentrations of 10 µg/mL and
higher and that the mixture did not significantly potentiate or antagonize PXR
activation by the receptor ligand, RIF. We then evaluated the ability of selected
PCB congeners to activate PXR (Fig. 4.3 C). Of the congeners tested, non-
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coplanar PCBs that significantly increased luciferase activity at 10 µM included
PCBs 149 (2.1-fold, p <0.0001), 138 (1.7-fold, p =0.0006), 187 (2.0-fold, p
<0.0001), 174 (2.3-fold, p <0.0001), 151 (1.6-fold, p =0.0062), 183 (1.6-fold, p
=0.0067) and 196 (1.6-fold, p =0.0036). Notably, these congeners in total
represent more than 30% of the Aroclor 1260 mixture by mass. Interestingly,
PCB 126, a well-known AhR ligand and a coplanar congener also activated
human PXR (1.9-fold, p <0.0001), indicating that a PCB’s non-coplanar structure
is not solely required for this receptor’s activation.
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Figure 4.3. Aroclor 1260 activation of the human PXR.
HepG2 cells were transiently transfected with the expression plasmid
pSG5-hPXR and reporter plasmid pGL3-DR4-Luc. Rifampicin (10 µM, RIF) was
used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5, 10, 15
and 20 µg/mL and luciferase induction was normalized and compared to DMSOexposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 10 µM RIF or
RIF plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. The luciferase induction was
normalized to that of cells exposed only to DMSO solvent carrier (as in A, not
shown). Luciferase activity in cells exposed to RIF and Aroclor 1260 was
compared to that of RIF-exposed cells. (C) Cells were exposed to selected PCB
congeners (10 µM) present in Aroclor 1260 and the induction was compared to
DMSO-exposed cells. Data were normalized to luciferase activity in cells
exposed only to DMSO and are expressed as mean ± SEM, n=4, * p <0.05.
Figure adapted from Wahlang et al., Toxicol Sci, 140 (2), 2014.
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Aroclor 1260 activation of the human constitutive androstane receptor
In these experiments, HepG2 cells were co-transfected with pCMV6hCAR (CAR2) and pGL3-DR4-Luc and the ability of Aroclor 1260 to transactivate
CAR2 was evaluated. CAR 2 is a human splice variant of the CAR1 reference
form of the receptor, but unlike the reference form, CAR2 is not constitutively
active; rather, it is a ligand activated receptor (138). Although somewhat modest,
the human CAR agonist CITCO and Aroclor 1260 (10 µg/mL) significantly
activated CAR2 (2.8-fold, p <0.0001 and 1.6-fold, p =0.0240 respectively) (Fig.
4.4 A). However, increasing the concentration of Aroclor 1260 did not lead to
further CAR2 activation (1.1-fold at 15 µg/mL and 1.4-fold at 20 µg/mL
respectively). Rather, this PCB mixture appeared to antagonize CAR2 activation
by CITCO (Fig. 4.4 B). Aroclor 1260, at 20 µg/mL, significantly reduced the
induction produced by CITCO by 51% (p =0.0314). These results suggested that
Aroclor 1260 may bind to CAR2 and either activate CAR2 or inhibit CAR2
activation by CITCO in a concentration-dependent manner. Interestingly, two of
the selected congeners, PCBs 187 (p =0.0042) and 126 (p =0.0031), increased
luciferase induction significantly at 10 µM concentration (Fig. 4.4 C), indicating
that some of the PCB congeners in Aroclor 1260 may be CAR2 agonists.
Given the apparent impact of these PCB congeners on human CAR, we
designed a complimentary series of assays to further corroborate and better
characterize these effects using the primate-derived cell line, COS-1. These
results are presented in Figure 4.5. Due to the high constitutive activity of CAR1,
any ligand interactions with the receptor tend to be masked. In these respects, it
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is notable that PCB 174 significantly inhibited the constitutive activity of CAR1 (p
<0.05), though not as remarkably as ANDR (p <0.001), a known CAR inverse
agonist (Fig. 4.5 A). Although the level of activation of CAR2 did not reach the
level of the CITCO positive control (5.4-fold, p <0.001), Aroclor 1260 as well as
several other PCB congeners demonstrated significant CAR2 activation in the
COS-1 cell assays (Fig. 4.5 B). Exhibiting a fold change of 2.4 (p <0.001), PCB
126 elicited the greatest response - even greater than Aroclor 1260 (1.7-fold, p
<0.05). Four additional congeners also activated CAR2: 180 (1.7-fold, p <0.05),
149 (1.9-fold, p <0.01), 187 (2.0-fold, p <0.001) and 196 (1.8-fold, p <0.01).
CAR3, another ligand activated human splice variant, which likely maintains a
conserved ligand binding pocket with CAR1, was also tested and exhibited
significant activation effects with Aroclor 1260 (7.6-fold, p <0.001) (Fig. 4.5 C).
Several other PCB congeners also demonstrated significant CAR3 activation
including PCB 187 (17.1-fold, p <0.001; comparable to CITCO at 18.5-fold, p
<0.001), PCB 153 (6.0-fold, p <0.01), PCB 149 (10.6-fold, p <0.001), PCB 138
(8.3-fold, p <0.001), PCB 151 (5.5-fold, p <0.01), and PCB183 (15.1-fold, p
<0.001).
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Figure 4.4. Aroclor 1260 activation of the human CAR2 transcript.
HepG2 cells were transiently transfected with the expression plasmid
pCMV6-hCAR (CAR2) and reporter plasmid pGL3-DR4-Luc. CITCO (10 µM) was
used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5, 10, 15
and 20 µg/mL and luciferase induction was normalized and compared to DMSOexposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 10 µM CITCO
or CITCO plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. The luciferase
induction was normalized to that of cells exposed only to DMSO solvent carrier
(as in A, not shown). Luciferase activity in cells exposed to CITCO and Aroclor
1260 was compared to that of CITCO-exposed cells. (C) Cells were exposed to
selected PCB congeners (10 µM) present in Aroclor 1260 and the induction was
compared to DMSO-exposed cells. Data were normalized to luciferase activity in
cells exposed only to DMSO and are expressed as mean ± SEM, n=4, * p <0.05.
Figure adapted from Wahlang et al., Toxicol Sci, 140 (2), 2014.
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Figure 4.5. Aroclor 1260 activation of the human CAR variant transcripts in
COS-1 cells.
COS-1 cells were transiently transfected with expression plasmid
pTracerCMV2 containing either (A) CAR1, (B) CAR2 or (C) CAR3 transcripts,
together with the reporter plasmid, pGL3-2B6XREM/PBREM-TKLuc. Cells were
exposed to selected PCB congeners (10 µM) present in Aroclor 1260 and the
induction was compared to DMSO-exposed cells. CITCO (5 µM) was used as a
positive control. ANDR (10 µM), a CAR inverse agonist, was used as a negative
control for CAR1. Data were normalized to luciferase activity in cells exposed
only to DMSO and are expressed as mean ± SEM, n=4, * p <0.05. Figure
adapted from Wahlang et al., Toxicol Sci, 140 (2), 2014.
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Effect of Aroclor 1260 on the human liver-X-receptor alpha
The human LXRα is a subtype of LXR that is expressed in the liver and its
under- or over-activation eventually leads to steatosis (143). We therefore
hypothesized that Aroclor 1260 may activate LXRα and this activation may
subsequently promote hepatic steatosis and NAFLD. HepG2 cells, co-transfected
with pSG5-hLXRα and pTK-LXRE-Luc, were exposed to various concentrations
of Aroclor 1260 for 24 h and the normalized luciferase activity measured.
T0901317, a synthetic LXRα ligand was used as a positive control. Compared to
the fold induction by T0901317 (100 nM), Aroclor 1260 did not activate LXRα nor
antagonize LXRα activation by T0901317 at any concentration tested (Fig. 4.6
A&B), thus indicating that this PCB mixture is neither an agonist nor antagonist of
the nuclear receptor LXRα.
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Figure 4.6. Aroclor 1260 activation of the human LXRα.
HepG2 cells were transiently transfected with the expression plasmid
pSG5-hLXRα and reporter plasmid pTK-LXRE-Luc. T0901317 (100nM, T) was
used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5, 10, 15
and 20 µg/mL and luciferase induction was normalized and compared to DMSOexposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 100 nM T or T
plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. Luciferase activity in cells
exposed to T and Aroclor 1260 was compared to that of T-exposed cells. Data
were normalized to luciferase activity in cells exposed only to DMSO and are
expressed as mean ± SEM, n=4, * p <0.05.
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Effect of Aroclor 1260 on the human farnesoid-X-receptor
The ability of Aroclor 1260 to activate FXR, a key regulator of bile acid and
energy metabolism was evaluated. HepG2 cells, co-transfected with pSG5-hFXR
and pGL3-IR1-Luc were exposed to various concentrations of Aroclor 1260 for
24 h. GW4064 (0.5 µM), a synthetic FXR agonist, was sed as a positive control.
GW4064 activated FXR whereas Aroclor 1260 did not induce a response at any
of the concentrations tested. In studies to test antagonism, all concentrations
tested were without effect on the activation of human FXR (Fig. 4.7 A&B). Thus,
this PCB mixture is neither an agonist nor antagonist for the human FXR.
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Figure 4.7. Aroclor 1260 activation of the human FXR.
HepG2 cells were transiently transfected with the expression plasmid
pSG5-hFXR and reporter plasmid pGL3-IR1-Luc. GW4064 (0.5 µM, GW) was
used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5, 10, 15
and 20 µg/mL and luciferase induction was normalized and compared to DMSOexposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 0.5 µM GW or
GW plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. Luciferase activity in cells
exposed to GW and Aroclor 1260 was compared to that of GW-exposed cells.
Data were normalized to luciferase activity in cells exposed only to DMSO and
are expressed as mean ± SEM, n=4, * p <0.05.
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Effect of Aroclor 1260 on the human peroxisome-proliferator activated
receptors
PPARs are a group of nuclear receptors that mediate peroxisomal
proliferation with subtype alpha (α) playing a distinct transcriptional role in lipid
metabolism in the liver and the subtype gamma (γ) in the adipose tissue. It was
therefore important to evaluate the effect of Aroclor 1260 on PPARs α and γ
activation. HepG2 cells were co-transfected with pCMV6-hPPARα and pGL3DR1-Luc. Nafenopin was used as a positive control. Aroclor 1260 did not activate
PPARα at any of the concentrations (Fig. 4.8. A). In studies to test antagonism,
Aroclor 1260 at the highest concentration (20 µg/mL) significantly antagonized
PPARα activation induced by nafenopin (27%, reduction, p =0.0222, Fig. 4.8. B).
Possible antagonism of PPARα by individual PCB congeners also was tested at
10 µM concentration (Fig. 4.8. C). However, none of the selected congeners
reduced the induction by nafenopin significantly, suggesting that a combination of
the congeners is required to produce a marked effect or that other congeners
present in this mixture may contribute to this effect.
For PPARγ activation, HepG2 cells were co-transfected with pCMV6hPPARγ and pGL3-DR1-Luc. Pioglitazone was used as a positive control.
Aroclor 1260 did not activate PPARγ nor antagonize PPARγ activation by
pioglitazone at any of the concentrations tested (Fig. 4.9. A&B).
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Figure 4.8. Aroclor 1260 activation of the human PPARα.
HepG2 cells were transiently transfected with the expression plasmid
pCMV6-hPPARα and reporter plasmid pGL3-DR1-Luc. Nafenopin (50 µM, N)
was used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5,
10, 15 and 20 µg/mL and luciferase induction was normalized and compared to
DMSO-exposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 50 µM N
or N plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. The luciferase induction was
normalized to that of cells exposed only to DMSO solvent carrier (as in A, not
shown). (C) Cells were exposed to selected PCB congeners (10 µM) present in
Aroclor 1260 and the induction was compared to DMSO-exposed cells.
Luciferase activity in cells exposed to N and Aroclor 1260 was compared to that
of N-exposed cells. Data were normalized to luciferase activity in cells exposed
only to DMSO and are expressed as mean ± SEM, n=4, * p <0.05. Figure
adapted from Wahlang et al., Toxicol Sci, 140 (2), 2014.
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Figure 4.9. Aroclor 1260 activation of the human PPARγ.
HepG2 cells were transiently transfected with the expression plasmid
pCMV6-h PPARγ and reporter plasmid pGL3-DR1-Luc. Pioglitazone (10 µM, P)
was used as a positive control. (A) Cells were exposed to Aroclor 1260 at 0, 5,
10, 15 and 20 µg/mL and luciferase induction was normalized and compared to
DMSO-exposed cells (0 µg/mL Aroclor 1260). (B) Cells were exposed to 10 µM P
or P plus Aroclor 1260 at 0, 5, 10, 15 and 20 µg/mL. Luciferase activity in cells
exposed to P and Aroclor 1260 was compared to that of P-exposed cells. Data
were normalized to luciferase activity in cells exposed only to DMSO and are
expressed as mean ± SEM, n=4, * p <0.05.
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Aroclor 1260 exposure and gene expression in human hepatocytes
To confirm our findings, we tested the effects of Aroclor 1260 exposure on
target gene expression profiles in human hepatocytes. Primary hepatocytes were
exposed to Aroclor 1260 at 5, 10, 15 and 20 µg/mL and gene expression was
measured by RT-PCR. The mRNA expression of target genes namely CYP1A1,
CD36, CYP3A4, CYP2B6, CPT1A, FAS and SHP were significantly induced by
the respective receptor agonists in primary human hepatocytes (Fig. 4.10. A).
Expression levels of CYP1A1, an AhR target gene were significantly
increased when hepatocytes were exposed to Aroclor 1260 (15 µg/mL, p
=0.0018, and 20 µg/mL, p =0.0066, vs. unexposed cells) (Fig. 4.10. B). Contrary
to CYP1A1, CD36, another AhR target gene was not induced by Aroclor 1260
exposure, suggesting that CD36 is not as inducible as CYP1A1 (Fig. 4.10. C).
CD36 expression, however, is regulated by other transcription factors in addition
to AhR (94). Furthermore, CYP3A4 (PXR target gene) mRNA expression was
upregulated by Aroclor 1260 exposure at 15 µg/mL (p =0.0083) and 20 µg/mL (p
=0.0303) (Fig. 4.10. D). Irrespective of the CAR2 antagonism observed in
transfection assays, Aroclor 1260 induced CYP2B6 (CAR target gene) at 15
µg/mL (p =0.0114) and 20 µg/mL (p =0.0036) (Fig. 4.10. E). Expression levels of
other genes including FAS (LXR target gene), SHP (FXR target gene) and
CPT1A (PPARα target gene) were not affected by Aroclor 1260 exposure (Fig.
4.10. F, G&H respectively), thus confirming our results obtained from the HepG2
and COS-1 series of experiments.
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Figure 4.10. Effects of Aroclor 1260 on target genes in primary hepatocytes.
Primary human hepatocytes were exposed either to receptor ligands or
different concentrations of Aroclor 1260. After a 24 hour incubation, RNA was
isolated and RT-PCR was performed. (A) The mRNA levels of selected receptor
target genes were upregulated by receptor ligands (positive control) namely BA
(10 µM) for CYP1A1 and CD36, RIF (10 µM) for CYP3A4, CITCO (10 µM) for
CYP2B6, T0901317 (100 nM) for FAS, nafenopin (50 µM) for CPT1A and
GW4065 (0.5 µM) for SHP. Relative mRNA levels of target genes were
measured in Aroclor 1260-exposed cells namely (B) CYP1A1, (C) CD36, (D)
CYP3A4, (E) CYP2B6, (F) FAS, (G) SHP and (H) CPT1A. Figure adapted from
Wahlang et al., Toxicol Sci, 140 (2), 2014.
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DISCUSSION
Our laboratory recently identified suspected NAFLD and toxicantassociated steatohepatitis in NHANES participants with low-level environmental
exposures to POPs, including 20 PCBs (18). Epidemiologic studies have shown
a positive association between adipose tissue concentrations of PCBs and type 2
diabetes (42, 144). High serum PCB levels were also associated with elevated
serum triglycerides and cholesterol which are major risk factors for
cardiovascular diseases (145). Exposure to PCB mixtures has also been
associated with elevated liver enzymes in plasma and hepatomegaly (53).
Clearly, chronic exposures to these chlorinated compounds appear to disrupt
both lipid and glucose homeostasis and consequently lead to diabetes and
associated metabolic disorders such as NAFLD. Therefore, identifying
mechanisms by which PCB exposure can lead to such deleterious effects is
relevant to public health.
Environmental exposure to POPs such as PCBs is a major health
concern, although subtly different from occupational exposure. The health effects
from occupational exposures are more related to the smaller more metabolizable
congeners and the subsequent formation of reactive potentially genotoxic
metabolites. In contrast, the effects produced by the non-metabolizable PCBs in
the body are expected to be chronic and life-long since they are not eliminated
from the system. Aroclor 1260 production represented approximately 10.6% of
total PCB production in the US between 1958-1977 which is modest compared to
Aroclor 1242 (51.7%) (146). Nonetheless, Aroclor 1260 was selected for this
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study because of the resemblance of congener composition pattern to that of
human fat (36).
Lipid-adjusted serum PCB levels were measured in NHANES participants
and the PCB exposed Anniston cohort and reported to range from 75-170 ng/g
(0.1 - 0.5 µM) (18, 46). Additionally, National Toxicology Program (NTP) studies
reported the following PCB levels in a 2-year gavage study in rats: lipid-adjusted
serum-4,650 ng/g; liver-64,593 ng/g; and adipose-2,495,994 ng/g (23). In these
studies, PCB liver levels were at least 10-fold higher and PCB adipose levels
were at least 200-fold higher than lipid-adjusted serum levels irrespective of the
dose administered. In our experiments, we used Aroclor 1260 at concentrations
ranging from 5-20 µg/mL (~10-50 µM) and selected congeners at 10 µM. These
concentrations should approximate the range seen in bio-accumulated
organs/tissues such as the liver and adipose tissue.
Almost all PCB animal studies have been performed in rodents, where
chronic toxicity is generally regarded as a function of the PCBs’ ability to interact
with AhR and nuclear receptors. There are clear differences in the ligand affinity
of these receptors, in rodents and humans, toward model ligands and xenobiotic
compounds, including PCBs. In order to understand more clearly the involvement
of PCBs in human NAFLD as demonstrated in human epidemiological studies
such as NHANES, it is important to understand specific interactions between
PCBs and human receptors. The findings from the current study demonstrate
that Aroclor 1260 activates PXR (Fig. 4.3) and to a lesser extent AhR (Fig. 4.2),
suggesting that congener composition is critical in determining a mixture’s
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mode(s) of action. The effect of Aroclor 1260 on the AhR is likely due to the
presence of coplanar congeners such as PCB 126. However, because these
coplanar compounds are only a small fraction of this mixture, a higher
concentration of Aroclor 1260 would be required to observe the “dioxin-like”
effects. PCB 138, a non-coplanar congener, may also be responsible for the
Aroclor 1260 effect on the AhR. Parkinson et al demonstrated that some di-ortho
substituted PCBs can induce hepatic microsomal benzo[a]pyrene hydroxylase,
consistent with AhR activation. Thus, coplanarity does not necessarily define
“dioxin like” PCBs from “non-dioxin like” ones (147).
The interaction between Aroclor 1260 and the AhR is further confirmed by
the CYP1A1 induction at higher exposure levels in primary hepatocytes (Fig.
4.10). The CYP1A1 induction by Aroclor 1260 however was much less than the
1000-fold induction by the AhR ligand, BA. Furthermore, CD36, another AhR
target gene was not induced by Aroclor 1260 vs. BA exposure in primary
hepatocytes, further suggesting that a higher concentration of Aroclor 1260 may
be required for “dioxin-like” effects. In contrast to AhR, Aroclor 1260 appears to
be a relatively good human PXR agonist as observed through transient
transfection assays and CYP3A4 induction in primary human hepatocytes. PXR
is a transcription factor that plays a distinct role in drug metabolism and recent
studies demonstrated its role in maintaining energy homeostasis in the body.
PXR activation is associated with decreased expression of genes involved
in lipid catabolism namely carnitine palmitoyltransferase-1a and 3-hydroxy-3methylglutaryl-CoA-synthase and increased expression of the lipogenic gene
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stearoyl-CoA desaturase1 which could contribute to NAFLD (105). Exposure to
PXR agonists also decreases blood glucose levels in fasting mice and this effect
is related to forkhead box O1 (FoxO1) sequestration by PXR (74). A recent study
by He et al. reported that ablation of this receptor in mice was protective against
diet-induced and genetic obesity and improved insulin resistance (77). PXR
activation clearly leads to disruption in the body’s energy balance and this may
be one of the mechanisms through which PCBs exert their effects on hepatic
energy metabolism. Using transient transfection assays, Tabb et al.
demonstrated that highly chlorinated PCBs including PCBs 184 and 197 inhibited
human PXR (148). However, PCB 184 is not a component of Aroclor 1260 and
PCB 197 accounts for only 0.07% of its total congener composition. This
concentration is not likely sufficient to inhibit human PXR. In our study, the
majority of PCBs in Aroclor 1260 appear to be PXR agonists.
As its name implies, wild type CAR is a constitutively active receptor due
to a truncation that prevents internalization of the transactivation domain (AF2)
and results in recruitment of co-activators. In vivo, CAR is regulated through its
sequestration in the cytosol by chaperone proteins. Upon ligand binding, the
receptor translocates to the nucleus and binds to its respective gene response
elements. The cytosolic localization process is absent in immortalized cell lines.
Consequently, performing transactivation studies in cell lines using in vitro
reporter-based systems can be challenging due to the absence of ligand
activation effect normally exhibited by CAR. However, in humans, the CAR
transcript is spliced into several variants, in particular CAR2 and CAR3 that
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constitute approximately one third of the CAR mRNA pool and encode functional
CAR proteins (138, 140). Interestingly, both CAR2 and CAR3 splice variants
have additional amino acids within the receptor’s ligand binding or
heterodimerization domain that function to configure these variants as ligandactivated receptors, unlike the parent CAR. Aroclor 1260’s interaction with
human CAR is perhaps crucial, given the fact that non-coplanar PCBs, such as
PCB 153, activate murine CAR target genes, including Cyp2b10. Of further
interest, CAR has recently been identified as an anti-obesity nuclear receptor
whose activation prevents obesity and improves type 2 diabetes through
inhibition of lipogenesis and improved insulin sensitivity (72).
A recent study by Al-Salman et al. demonstrated that non-coplanar PCBs,
namely PCBs 153, 180 and 194, are agonists for the human PXR and CAR at 10
µM (97). In that study, a receptor activation assay was performed in Huh7 cells
using Checkmate mammalian two hybrid system where activated PXR/CAR bind
to the DNA-binding domain of the NR Gal4 fusion plasmid. In the current
investigation, we deployed a series of transactivation assays to evaluate the
potential role of various PCB congeners to activate human CAR/PXR directly. In
HepG2 cells, Aroclor 1260 activated CAR2 at 10 µg/mL but not at higher
concentrations (Fig. 4.4). The mixed agonism/antagonism observed with CAR2
appeared concentration-dependent with antagonism seen at higher
concentrations. In additional studies conducted with COS-1 cells, the results
obtained with CAR3 were particularly intriguing, in that several PCB congeners
were identified as human CAR activators (Fig. 4.5), in particular, PCBs 187, 183,
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149, 138, as well as Aroclor 1260 (ranked in decreasing order of potency). CAR3
is likely a highly sensitive and reasonable surrogate for CAR1, based on previous
reports that include modeling of the receptors’ ligand binding pockets (140, 149),
whereas CAR2 appears to possess subtle alterations within its binding pocket
that modify its ligand interaction profile compared with CAR1 (150).
In other experiments, Aroclor 1260 exposure induced the CAR target
gene, CYP2B6 in human hepatocytes, indicating that this agent acts primarily as
a CAR activator and not antagonist. This result is consistent with the activation
profile exhibited by Aroclor 1260 on human CAR3 in the transactivation assay.
However, it should be noted that ligand binding to CAR is not the sole
mechanism by which CAR is activated. Recently, Mutoh et al. reported that
phenobarbital, a well-known CAR agonist, indirectly activated CAR by inhibiting
the epidermal growth factor receptor signaling which subsequently
dephosphorylated CAR and mediated its translocation into the nucleus (151). We
anticipate that some of the PCB congeners may not directly interact with CAR,
but may act through the same mechanism as phenobarbital. Further studies will
be required to test this possibility.
Previous studies showed that co-exposure to PCB 153 and high fat diet
worsened NAFLD and obesity in male C57Bl/6 mice through upregulation of fatty
acid synthase, an LXRα target gene (48). However in the current study, Aroclor
1260 interacted with neither LXRα nor FXR. Although there was no direct effect
by PCBs on either LXRα or FXR, we cannot rule out the possibility of an indirect
interaction via cross-talk or alterations in nuclear receptor expression. However,
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nuclear receptor cross-talk is complex and not well established especially in
relation to PCBs. Therefore more studies are required to elaborate on the
possibility of cross-talk. Aroclor 1260 did not activate PPARα but it antagonized
PPARα activation by nafenopin at higher concentrations (Fig. 4.8). However,
none of the congeners tested at 10 µM exhibited any antagonism. Robertson et
al. reported the suppression of peroxisomal enzyme activities and CYP4A
expression in male Sprague-Dawley rats treated with co-planar PCBs, including
PCBs 77, 122, 126 and 169 (98). Considering the fact that Aroclor 1260 has a
lesser percentage of coplanar PCBs than non-coplanar structural components,
we may reconcile the possibility that a higher concentration of this PCB mixture
may be required to antagonize PPARα whereas PPARγ remained unaffected.
In summary, Aroclor 1260 is an activator of human PXR and CAR 2/3
variants. It also appears to activate human AhR and to antagonize human
PPARα at higher concentrations. The current study is clinically relevant because
human receptor activation by a PCB mixture that simulates PCB bioaccumulation
in humans was examined at relevant concentrations. Furthermore, the effects of
PCBs on human nuclear receptors such as LXRα and FXR and in human
hepatocytes have never been assessed before. Additionally, this is the first study
to evaluate PCB activation on the CAR variants. Because PCB exposures have
been associated with obesity, NAFLD and metabolic syndrome and these
disorders are intimately involved with nuclear receptor activation, the results
clearly provide new insight into potential mode(s) of PCB action in human
NAFLD.
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CHAPTER 5
OVERALL SUMMARY
Overall goal and specific aims
PCBs are persistent organic pollutants that dose-dependently increase the
risk for liver injury as observed from epidemiologic studies. These polyhalogenated compounds persist in the ecosystem and the heavily chlorinated
congeners bio-accumulate in living organisms. As stated previously, the
commercial PCB mixture, Aroclor 1260 has a congener composition
representative of bio-accumulated PCBs. Aroclor 1260 was therefore chosen for
this dissertation project to simulate human PCB exposure patterns. Furthermore,
PCBs are predicted to interact with most receptors previously implicated in
xenobiotic/energy metabolism and NAFLD. These receptors include the AhR,
PXR, CAR, PPARs, LXRα and FXR. To determine if PCB exposure play a causal
role in the development of NAFLD and steatohepatitis, and to gain insight into the
mechanisms involved, the in vivo studies were undertaken using Aroclor 1260 at
doses that correlated to human PCB body burden. The overall objective of the
dissertation project was to evaluate the role of PCB exposure, using Aroclor
1260, in fatty liver disease and to elucidate the potential PCB-receptor
interactions that mediate fatty liver disease. To fulfill our objective, the following
specific aims were proposed and carried out.
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1A. Develop a mouse model for PCB exposure that simulates human
exposure paradigms.
1B. Evaluate the effects of the commercialized PCB mixture, Aroclor 1260,
in obesity and NAFLD.
2. Determine the role of the nuclear receptors, CAR and PXR, in liver
injury caused by Aroclor 1260 and high fat diet co-exposure.
3. Examine the interactions between Aroclor 1260/selected PCB
congeners and human receptors in the liver
Major findings of this dissertation
The experiments described in Chapter 2, 3 and 4 addressed Specific Aim
1, 2 and 3 respectively. The major findings from each Chapter are discussed in
the following paragraphs.
1. Evaluating the effects of Aroclor 1260 exposure in a diet-induced obesity
mouse model
Prior to initiating the animal studies, there were no documented studies on
chronic HFD+PCB co-exposed animal models that simulate human exposure
patterns. We therefore developed an animal model for studying the effects of
PCB exposure at doses that were relevant to human exposure. Aroclor 1260 was
administered to C57Bl/6 mice at 20 or 200 mg/kg via oral gavage in corn oil. The
low dose (20 mg/kg) was designed to mimic the maximum human PCB
exposures seen in the Anniston cohort and the high dose (200 mg/kg) was based
on doses used in the NTP rodent carcinogenesis studies (18, 22).
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It was observed that relevant doses of Aroclor 1260 along with HFD coexposure caused toxicant-associated steatohepatitis in a mouse model of dietinduced obesity. In contrast to our previous study wherein a single congener
(PCB 153) was used, this PCB mixture neither increased the body
weight/visceral adiposity nor worsened insulin resistance/diet-induced obesity.
On the contrary, Aroclor 1260 exposure was associated with decreased body fat
in HFD-fed mice but had no effect on blood glucose/lipid levels. In fact, Aroclor
1260 at higher doses appeared to reduce diet-induced obesity by decreasing the
% increase in bodyweight gain (Fig. 2.2). Paradoxically, Aroclor 1260+HFD coexposed mice demonstrated increased inflammatory foci at both doses while the
degree of steatosis did not change. Serum cytokines (Fig. 2.5) and hepatic
expression of IL-6 and TNFα (Fig. 2.9) were increased only at 20 mg/kg,
suggesting an inhibition of pro-inflammatory cytokine production at the 200 mg/kg
exposure. Aroclor 1260 exposure induced hepatic expression of cytochrome
P450s including Cyp3a11 (PXR target gene) and Cyp2b10 (CAR target gene) but
Cyp2b10 inducibility was diminished with HFD-feeding (Fig. 2.10). Cyp1a2 (AhR
target gene) was induced only at the higher dose (200 mg/kg). There was a
significant difference between the low and high exposure doses in terms of
hepatic/systemic inflammation, which could potentially be due to AhR activation.
Aroclor 1260 activated CAR and PXR and to a lesser extent AhR, suggesting
congener composition and exposure levels to be critical in determining a
mixture’s mode(s) of actions.
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2. Evaluating the role of CAR and PXR in liver injury caused by Aroclor
1260 exposure in conjunction with HFD
In Chapter 2, it was demonstrated that Aroclor 1260 at 20 and 200 mg/kg
activated nuclear receptors CAR and PXR (152). In chapter 3, the role of CAR
and PXR in Aroclor 1260+HFD-induced steatohepatitis was further evaluated.
C57Bl/6 (WT), PXR knockout and CAR knockout mice were exposed to Aroclor
1260 (20 mg/kg) and fed a high fat diet (42% kCal fat) for 12 weeks. Consistent
with our previous findings, Aroclor 1260 exposure resulted in the transition of
diet-induced steatosis to steatohepatitis and this was independent of the mouse
genotype (Fig. 3.5). Basal hepatic TNFα expression was increased in the
knockout groups independent of exposure (Fig. 3.6), indicating an antiinflammatory role of these receptors in NASH. Moreover, the PXR knockout mice
had increased % body fat accompanied with decreased lean tissue mass and
increased liver to body weight ratio, regardless of exposure (Fig. 3.1).
An intriguing finding from this study was that Aroclor 1260 exposure
decreased serum insulin levels and HOMA-IR in all groups (Fig. 3.8). This finding
correlated with findings from the Anniston Community Health Survey studies
where serum insulin decreased with increasing PCB body burden (153). This
was a paradoxical finding, because PCB exposure was associated with diabetes
in this population and diabetes is normally associated with an increase in HOMAIR, hence increased insulin levels and insulin resistance. The results suggested
that PCBs may have an effect on insulin secretion and pancreatic function.
Interestingly, a recent chronic exposure study using Aroclor 1254 reported
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hyperinsulinemia in lean and diet-induced obese mice (49). However, the
congener composition in Aroclor 1254 is strikingly different from that of Aroclor
1260 (146), with the former containing higher amounts of dioxin like PCBs.
Therefore, congener composition as well as the dose used may play a role in the
observed hyperinsulinemia.
The PXR knockout mice exposed to Aroclor 1260 showed a robust
increase in hepatic gluconeogenic gene (PEPCK-1, G6Pase) expression (Fig.
3.9), suggesting that PXR may be a major repressor of the gluconeogenic
transcription factor, FOXO1. In terms of lipogenic gene expression, Aroclor 1260
exposure decreased FAS and SCD1 mRNA levels in the WT group. However,
the knockout groups had higher levels of basal FAS and SCD1 expression
irrespective of Aroclor 1260 exposure (Fig. 3.11). This could be explained by the
increase in basal mTOR1 activity in these groups as activated mTOR1
corresponds to an increase in lipogenesis through nuclear localization of the
lipogenic transcription factor, SREBP1 (113). On the other hand, Aroclor 1260
exposure resulted in AMPKα activation which was consistent with an increase in
hepatic expression of the glucose transporters (Fig. 3.13). AMPKα activation by
Aroclor 1260 was manifested by the increase in RER in the knockout groups that
were exposed to Aroclor 1260 (Fig. 3.3). Furthermore, both knockout groups
demonstrated increased movement in the light cycle with Aroclor 1260 exposure,
suggesting that this increase in physical activity may have driven AMPKα
activation. However, the exact mechanism as to why Aroclor 1260 exposure
caused hyperactivity in these animals remains to be investigated.
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In summary, CAR and PXR activation appeared to be protective with
regard to inflammation, lipogenesis and gluconeogenesis. However, CAR and
PXR activation was not sufficient to protect the animals from developing NASH.
This was possibly due to mechanisms independent of CAR and PXR activation
such as compromised insulin levels and no improvement in obesity inspite of the
improved leptin to adiponectin ratio. Moreover, the NASH symptoms that were
observed in these animals such as insulin resistance and steatosis were
uncoupled as compared to typical NASH hallmarks. We conclude that although
CAR /PXR activation played a protective role in NASH induced by PCB+HFD,
there are other receptor-based mechanisms responsible for the development of
NASH that need to be addressed in this PCB/HFD model.
3. Human receptor activation by Aroclor 1260 and selected individual PCB
congeners
The studies in this Chapter evaluated Aroclor 1260 and selected
congeners, as potential ligands for human receptors utilizing human hepatomaderived (HepG2) and primate-derived (COS-1) cell lines, and primary human
hepatocytes. It is important to differentiate between rodent and human receptor
activation because, although these receptors are highly conserved between
species, some of these receptors such as the AhR vary in terms of ligand binding
sites and target genes that they induce. The observed data suggested that
Aroclor 1260 is a human AhR (Fig. 4.2), PXR (Fig. 4.3), a mixed
agonist/antagonist for CAR2 (Fig. 4.4), a CAR3 agonist (Fig. 4.5) and an
antagonist for human PPARα (Fig. 4.8). This study is clinically relevant because
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human receptor activation by a PCB mixture that simulates PCB bioaccumulation
in humans was examined at relevant concentrations. Furthermore, the effects of
PCBs on human nuclear receptors such as LXRα and FXR and in human
hepatocytes have never been assessed before. Additionally, this is the first study
to evaluate PCB activation on the human CAR variants. Because epidemiologic
studies have reported associations between PCB exposure and NAFLD, and
since these disorders are intimately involved with nuclear receptor activation, the
results clearly provide new insight into potential mode(s) of PCB action in human
NAFLD.
Strengths of this dissertation
There is much strength in this dissertation. First and foremost, an animal
model that simulated human PCB exposure patterns was developed. Secondly,
we have identified steatohepatitis caused by PCB exposure in a diet-induced
obesity mouse model and validated that the effects of a PCB mixture (Aroclor
1260) vary from that of a single congener (PCB 153). The work has also provided
insights in the underlying mechanism associated with PCB exposure such as
dose- and diet-dependent activation of human and murine receptors including the
AhR, CAR and PXR. Additionally, the results in this dissertation also answered
key questions related to the role of CAR and PXR in hepatic energy metabolism
and demonstrated the protective role of these receptors in PCB+HFD-induced
liver injury.
Another major strength of this dissertation includes the identification of
PCB-mediated NASH effects that are dissociated from typical NASH hallmarks
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such as the absence of insulin resistance. Furthermore, our observations of
PCB-mediated NASH that resulted in a unique animal phenotype correlated with
the observations seen in the PCB-exposed human population studies (153).
Inspite of focusing on CAR and PXR, we have also distinguished other factors
that play a role in PCB+HFD-induced liver injury such as the energy sensors,
mTOR1 and AMPKα. The knockout studies demonstrated that chronic
dysregulated receptor activation ensues in the PCB/HFD model that impact
energy metabolism and liver injury.
Limitations of this dissertation
The primary limitation of this dissertation is that the hepatic and adipose
concentrations of PCBs have not yet been quantified. This could potentially be
done in the future using mass spectrophotometry. Quantifying the amount of
PCBs in liver and fat will give us an idea of PCB compartmentalization in either a
low fat diet or HFD setting. Another limitation in the animal studies is that the
pancreatic tissues were not harvested for analysis. Therefore, we failed to look at
the effects of Aroclor 1260 exposure on pancreatic function and subsequently,
insulin secretion. An additional caveat in the experimental design of the in vivo
studies is that the mice received Aroclor 1260 either at a single exposure (20
mg/kg) or four separate exposures (50 mg/kg) rather than the intermittent
exposures that humans encounter from eating PCB- contaminated food.
Furthermore, another drawback of this dissertation was using serum ALT/AST as
a NASH biomarker based on low sensitivity, and evaluating other biomarkers is a
possibility in future studies (50). In addition, for the knockout animal studies, a
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2x2 ANOVA using SigmaPlot was used for statistical analysis. However, a more
rigorous approach would be using the SAS/SPSS Programs to perform contrast
and multiple correction tests and this will be accomplished in the near future.
Lastly, all our in vivo studies were performed using male mice; hence it is
pertinent to note that the observed effects may vary with gender and species,
especially since PCBs may also modulate the estrogen receptor.
Future directions
Although the studies described in the dissertation have answered
numerous questions related to the effects of PCB exposure on NAFLD and
obesity, the research studies have also raised a number of questions that need
to be addressed further. Future research studies directed form this work are as
follows:
1. Evaluate the underlying mechanisms that resulted in decreased serum
insulin levels with Aroclor 1260 exposure.
The animal studies clearly pointed out that Aroclor 1260 exposure was
associated with a decrease in serum insulin levels. However the exact
mechanisms that led to decreased insulin levels were not evaluated in these
studies. Insulin is synthesized within the β-cells of the Islets of Langerhans in the
pancreas and its secretion is triggered by various stimuli including increased
blood glucose levels (154). A 2-year study on a binary mixture of PCB 126 and
PCB 153 by the NTP reported the development of pancreatic cancer in female
SD rats (22). However, till date there are no studies reporting the effects of PCB
exposure on pancreatic function, either in experimental animal models or in
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epidemiologic studies. Therefore, the first logical step toward understanding the
mechanisms behind the PCB-mediated decreased serum insulin levels is to
examine the effects of PCB exposure on pancreatic structure and function.
2. Define the direct vs. indirect PCB activation of CAR.
In Chapter 2 and 3, we demonstrated that Aroclor 1260 exposure
activated CAR by inducing its target gene, Cyp 2b10. CAR activation can occur
either by direct binding to the receptor itself or indirectly through epidermal
growth factor receptor (EGFR) signaling. Phenobarbital, a prototypical CAR
ligand activates CAR indirectly by inhibiting the EGFR signaling which
subsequently dephosphorylated CAR and mediated its translocation into the
nucleus (151). We anticipate that some of the PCB congeners may not directly
interact with CAR, but may act through the same mechanism as phenobarbital.
Further studies will be required to test this possibility. Interestingly, EGFR
signaling promotes pancreatic β-cells expansion in response to a high nutrient
state and in pregnancy (155, 156). It would be insightful to look at PCB-EGFR
interactions since this may also answer questions related to the impact of PCB
exposure on pancreatic function and insulin secretion.
3. Investigate the effects of HFD feeding on CAR and PXR activation.
Regardless of Aroclor 1260 exposure, it appeared that HFD consumption
reduced the induction of CAR/PXR target genes as compared to CD
consumption. HFD feeding reduced Cyp2b10 induction by approximately 235fold and 41-fold vs. CD feeding at 20 mg/kg and 200 mg/kg, respectively. These
results appear consistent with previous studies (100, 101), and indicate that the
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ability of CAR to activate target genes is compromised when animals are fed with
HFD. We speculate that dietary components may interfere with CAR/PXR
activation and therefore, it would be interesting to look at the effects of other diets
such as high fructose diet. Another possibility is that the diet-induced steatosis
may alter PCB compartmentalization and therefore PCB concentrations in the
liver may vary, leading to lowered CAR/PXR target gene induction.
4. Study the neurological effects of PCB exposure pertaining to physical
activity.
Because metabolic chamber studies indicated that Aroclor 1260 exposure
increased movement in the knockout mice, it is worthwhile to study the PCBmediated effects in the brain. Studies have shown different PCB congeners
interacting with the ryanodine receptor (157, 158), as well as dopamine and
GABA neurotransmission (159, 160), and this could potentially impact motor
activity. Although looking at PCB-mediated neurological effects is beyond the
scope of an environmental liver disease laboratory, we can however collaborate
with other groups that study PCB-mediated effects on the central and peripheral
nervous system.
5. Elucidate the role of the AhR in PCB+HFD-induced liver disease.
The role of the AhR in steatosis and NAFLD has been investigated with
studies showing that AhR activation is consistent with upregulated CD36 and
SCD1 (110, 161). Using an AhR knockout or an AhR/CAR/PXR triple knockout
mouse model will provide insight into the role of the AhR in our PCB/HFD mouse
model. Another approach in this context is to use a binary mixture of Aroclors
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such as Aroclor 1260 that has primarily non-dioxin like PCBs and Aroclor 1254
that has mostly dioxin like PCBs. This will result in a PCB mixture that has
approximately 15 to 30-fold more AhR activity than the one currently studied.
6. Translate the animal findings to the PCB-exposed human population.
The objective of this dissertation is to understand the role of PCB
exposure in NAFLD, diabetes and obesity using animal models. We aim to
translate our animal findings to the PCB-exposed human population so as to
identify potential therapeutic targets that could be utilized to address the health
disorders associated with this population. We will be using humanized AhR, CAR
and PXR mice in our future studies to obtain data that is more relevant toward
evaluating the PCB effects in humans.
Conclusion
Overall, Aroclor 1260 exposure resulted in the transition of steatosis to
steatohepatitis in HFD-fed mice, thereby acting as a ‘second hit’ in diet-induced
steatohepatitis. Aroclor 1260-induced NASH could involve activation of novel
PCB receptors such as CAR and PXR or even non-receptor based modes of
action. Both PXR and CAR are required to maximally attenuate Aroclor 1260induced changes in body composition, carbohydrate/lipid metabolism and
inflammation in NASH. This is in stark contrast to hepatic steatosis induced by
dioxin which is dependent on AhR activation (161). Also, CAR and PXR
activation appeared to be protective in PCB-mediated toxicity but HFD
consumption decreased the protective CAR/PXR activation, illustrating the
importance of dietary co-exposures in PCB-related NASH (Fig. 5). Lastly, PCBs
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also interact directly with human receptors, implicating the potential role of these
receptors as therapeutic targets for NASH and environmental liver disease.
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Figure 5.1. Environmentally-relevant PCB-diet interactions mediate the
transition of steatosis to steatohepatitis.
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PROFESSIONAL MEMBERSHIPS
2014-present

Risk Assessment Specialty Section

2013-present

American Society for Pharmacology & Experimental
Therapeutics.

2013-present

Molecular and Systems Biology Specialty Section

2013-present

Ohio Valley SOT Regional Chapter

2013-present

Occupational and Public Health Specialty Section

2013-present

Society of Toxicology.

2012-present

Kentucky Academy of Science.
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2009-2010

American Association of Pharmaceutical Scientists (AAPS)
NIPER Student Chapter.

PROFESSIONAL TRAINING AND DEVELOPMENT
2014

Completed CEd-Tox course “Basic Principles in Human Risk
Assessment”

2013

Grant Writing Academy, University of Louisville.

2009

Online general course on Intellectual Property Rights, WIPO,
Switzerland.

LEADERSHIP
2014

Member, Communications Subcommittee, GSLC, SOT.

2014

Member, Graduate Student Leadership Committee, SOT.

2014

Student Representative, Ohio Valley SOT Student Chapter.

2012

Treasurer, American International Relations Club (AIRC),
University of Louisville.

2011

Public Relations Officer, AIRC, University of Louisville.

2009

Secretary, Pharmaceutics Club, NIPER.

AWARDS AND HONORS
2014

Graduate Dean’s Citation

2014

2nd Place, PhD Platform Presentation, OVSOT Annual
Meeting
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2014

KC Huang Outstanding Graduate Student Award 2013

2014 & 2012

Sponsored Research Tuition Award, School of
Interdisciplinary and Graduate Studies, University of
Louisville.

2014 & 2013

Travel Award, Graduate School Council, University of
Louisville.

2013

Best PhD Platform Presentation, OVSOT Annual Meeting.

2013

Travel Award, School of Medicine Research Committee,
University of Louisville.

2011

Finalist, Research! Louisville Graduate Poster Session.

2010-2012

Integrated Programs in Biomedical Sciences Fellowship

2009

Runner up, Business Plan, 81MG, NIPER.

2008

All India 119th Rank, General Aptitude Test in
Engineering, IIS Bangalore, India.

SERVICE: ACADEMIC AND COMMUNITY-RELATED
2014

Volunteer/Attendee, Midwest Membrane Trafficking &
Signaling Symposium, Louisville.

2014

Proctor, Patient SIMS on Autonomics, School of Medicine,
University of Louisville.

2014

Organizer, OVSOT Annual Summer Student Meeting

2014

Judge, Manual High School Science Fair.

2013-present

Member, Golden Key International Honor Society,
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University of Louisville.
2013-summer

Volunteer, Children's Hospital Foundation, Kosair
Children’s Hospital, Louisville, K.Y.

2012-present

Member, University of Louisville Study Abroad.

2011-present

Member, Indian Students Association, University of
Louisville.

2008-2006

Member, Indian Pharmaceutical Graduate Association
(IPGA).
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